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ABSTRACT

A PEPTIDE-BASED PLATFORM FOR DISPLAYING ANTIBODIES
TO ENGAGE T CELLS

By
Ying Zheng
December 2010

Dissertation supervised by Wilson S. Meng, Ph.D.
This study investigated a strategy by which antibodies were displayed on a gel-like
substance to engage T cells. The substance, a peptidic composite, was characterized in
vitro and explored as an injectable system in vivo. The composite consists of two
amphiphilic peptides, AEAEAKAKAEAEAKAK (referred to as “EAK”) and
AEAEAKAKAEAEAKAKHHHHHH (“EAKH6”). Spectroscopic analysis showed the
two peptides integrated into a single structure. Prior to combination, conformational
analysis revealed that EAKH6 adopts a mixed -helix/-strand conformation. In the
presence of EAK, EAKH6 exists predominantly in a -strand conformation. Using
nickel-bound horseradish peroxidase as a probe, the composite of EAK-EAKH6 was
found to display His-tags. T-cell-specific antibodies were found stably displayed on the
iv

EAK-EAKH6 assembly using recombinant protein A/G and anti-hexahistidine antibody
as an adaptor. When mounted with an anti-CD4 antibody, the system was shown to
capture CD4 T cells in a mixed population of lymphocytes. Antibodies were concentrated
in the subcutaneous space in mice when co-administered with EAK and EAKH6 along
with protein A/G and anti-hexahistidine antibody as an aqueous (deionized water)
solution. Taken together, these results indicate that the design can be used as a platform
for engaging specific subsets of leukocytes for purpose of immune modulation.

v
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CHAPTER 1
INTRODUCTION

Monoclonal antibodies (mAb) represent an important class of therapeutics. In the
United States alone, more than 20 antibody and similar molecules are currently approved
for a variety of diseases, including cancer, autoimmune and inflammatory diseases.

[1, 2]

Of the 26 new drugs approved in 2009 by the U.S. Food and Drug Administration, four
are mAb. Currently, more than 200 Abs are presently in various stages of clinical
development.[1] Among these are several that aim to modulate functions of T cells
through blocking or activating cell surface molecules, including CD3, CD4, CD25, and
cytotoxic T lymphocyte antigen-4 (CTLA4).[2,

3]

These modes of action preserve the

overall T cell populations but alter a subset of cells in order to modify the course of the
disease.
Normally, T cells accumulate and recirculate within secondary lymphoid organs
(spleen and lymph nodes). In pathological conditions, these lymphocytes flux robustly to
diseased locales to release cytokines and factors that, in most instances, sustain or
accelerate the condition. For example, T cells reactive against antigens expressed by
islets of Langerhans infiltrate into pancreas of patients with insulin-dependent diabetes
mellitus. [4] In malignant cancers, regulatory T (Treg) cells populate tumors and promote
tumorigenesis by suppressing the functions of other immune cells.[5] The rationale for
using antibodies is that the high specificity and binding strength of antibodies allow them
to bind to the target cells or block the signal pathway, leading to the depletion or
1

deactivation of the bound T cells. In pre-clinical and clinical settings of cancer or
autoimmunity, T cell-specific antibodies are typically administered systemically.

[3, 6, 7]

Consequently, all T cells (and sometimes other leukocytes that express the target epitope)
are affected, leading to non-specific immune modulation, which can result in adverse
events in patients.[8] Thus, the intrinsic specificity of an anti-T cell mAb is lost when
delivered systemically. Proposed here is a strategy by which disease-driving T cells
operating locally can be selectively engaged (and altered phenotypically) as a means to
induce specific immune modulation.
The peptide AEAEAKAKAEAEAKAK (single amino acid code; hereafter “EAK”)
self-assembles into high-molecular-weight structures.[9] The EAK sequence encompasses
periodic repeats of alternating polar and nonpolar residues. In pure water, the peptide
adopts a β-strand conformation in which the polar and non-polar side chains orient
toward opposite sides. In the presence of monovalent metal ions, the β-strands selfassociate into nano-scaled fibers through inter-sheet ionic pairing between charged
residues (glutamate and lysine) and hydrophobic interaction between alanines.[9-11]
Subsequent spontaneous cross-linking of the fibers yields quaternary β-sheet structures
resistant to acids and proteases.[11] These networks of interwoven peptidic fibers have
been explored as scaffolds for tissue growth or regeneration through cell attachments.[12]
Such matrices have the potential to provide molecular cues for a variety of cells to grow
and differentiate. An area of application that has not been explored is to use the fibrillar
structures to enhance the therapeutic functions of Abs. The objective is to use mAb to
intercept migratory leukocytes participating in cancer pathogenesis. The central

2

hypothesis of this research is that an injectable EAK-based system can be developed to
engage specific T cells via monoclonal antibodies.
To transform EAK matrices into a structure that will engage specific cells, a versatile
recognition mechanism is needed. To this end, a modified EAK peptide with six
consecutive histidines (H6) appended at the C-terminus was used to introduce binding
sites. The H6 domain is recognized by anti-polyhistidine antibodies and metal ions such
as nickel through coordination bonds, making this a multifunctional platform. The
modified peptide, referred hereafter as “EAKH6”, was designed on the basis that the
amphiphilic domain (AEAEAKAK)2 would intercalate into the crossed β-sheets of EAK
to form a composite in which H6 domains extend from the peptide assembly. We
envisaged that the histidine appendage would not hinder the ability of the amphiphilic
domain in EAKH6 to engage the same as in EAK. In the meantime, it is hypothesized
that the incorporation of EAKH6 does not interfere with the self-association of EAK.
This work was motivated by the need for new strategies to localize anti-T cell Ab to
the site of action. Described herein are characteristics of a peptide-based system
developed as an Ab displaying platform, made possible by the use of a bi-functional
peptide containing a β-strand domain and a H6 domain. Integration of EAKH6 into EAK
β-sheets was confirmed in that a composite of the two contained imidazole, the side chain
of histidine. EAKH6 appeared to transit from a mixed α-helix/β-strand conformation to a
predominately β-strand conformation in the presence of EAK. Display of functional H6
domains in the EAK-EAKH6 composite was evidenced in the experiments showing that
HRP-Ni and IgG were captured through coordination bonds or via the adaptor protein
A/G complexed with anti-H6 Ab, respectively. EAK-EAKH6 but not EAK capture cells
3

when mounted with anti-CD4 IgG; a subset of CD4+ T cells expressing CD25 and Foxp3
was depleted form cell suspensions containing different lymphocytes. Thus, the EAK
structure was transformed from a non-specific matrix to a cell-selective structure in EAKEAKH6 construct. The system proved to be amenable as an injectable material. In vivo, a
solution of EAK, EAKH6, protein A/G, anti-H6 Ab and IgG-PE injected subcutaneously
associated to concentrate the fluorescent Ab at the injection site for at least 24 h. The
EAK-EAKH6 composite thus serves to cluster antibody molecules. Such clustering
reduces the entropic loss upon antigen binding, thereby increasing the collective avidity
of the Ab. This should in theory result in superior efficacy of EAK-EAKH6 associated
Ab compared to free Ab.
This dissertation consists of nine chapters. Chapter 1 provides an overview of the
work that includes a brief introduction to mAb, the design of EAK-EAKH6 composite,
and the main experimental results and conclusions. Within the chapter an elaboration of
the central hypothesis and the scope of the work can be found. In Chapter 2 the
significance of the research is discussed. The advantage of using EAK-EAKH6 assembly
to cluster antibodies with increased avidity is addressed. Chapter 3 provides a review of
literatures concerning the background information as well as relevant recent studies and
discoveries. The first part concerns T cell differentiation and activation in health and
diseases. In particular, the change of Treg cells in cancer patients. Secondly, the
mechanisms and factors governing assembly of amphiphilic peptides are addressed.
Applications of peptide scaffolds in drug delivery and 3-D cell cultures are also reviewed.
Chapter 4 presents analytical data supporting the formation of EAK-EAKH6 composite.
Spectroscopic data confirming the presence of EAKH6 in the composite are provided.
4

The mechanism of EAKH6 integration into EAK is also addressed. The function and
stability of H6 domains were evaluated. Chapter 5 reports the feasibility of using protein
A/G as an adapter to load the EAK-EAKH6 composite with antibodies. Evidence of
formation of the antibody-mounted peptide assembly in vivo is also presented. Chapter 6
details the investigation of the capability of anti-CD4 EAK-EAKH6 assembly to capture
Treg cells. Chapter 7 describes the development and characterization of submicron
PLGA particles used to deliver nucleic acids, particularly, the encapsulated
oligodeoxynucleotide (ODN) and the surface adsorbed siRNA. The improved in vitro
uptake efficiency to primary mouse leukocytes is reported. The investigation of in vivo
function of siRNA carried by PLGA particles in mouse melanoma model is also
described. These particles may be loaded onto the EAK-EAKH6 as a drug delivery
module. Chapter 8 is a narration of the overall conclusions of the studies and
contributions of this research to the biomaterial community. The last chapter is included
as chapter 9, for it contains data generated outside the scope of the work towards testing
of the main hypothesis.

5

CHAPTER 2
SIGNIFICANCE OF THE RESEARCH
First introduced by Köhler and Milstein in 1975, mAb represent a mainstay in
biological therapeutics and biotechnology.[1, 13] The mechanisms by which mAb modulate
the functions of their target antigens are diverse. These include binding and neutralizing
soluble cytokines and growth factors to prevent them from activating their cognate
receptors. An example for this is the first therapeutic antibody, infliximab (Remicade;
Centocor/Merck), which binds tumor necrosis factor (TNF). Binding of ligands to
receptors can also be blocked by mAb directed to their cognate receptors and inhibit
receptor activation or function, for example, tocilizumab (Actemra/RoActemra;
Chugai/Roche) targeting the IL-6 receptor. Another class of mAb binds to cell surface
antigens and depletes antigen-bearing cells through complement-mediated lysis and
opsonization, as well as Fc receptor for IgG mediated clearance. Rituximab
(Rituxan/Mabthera; Genetech/Roche/Biogen Idec), which is a chimeric CD20-specific
antibody, succeeded in achieving B cell depletion in lymphoma patients. Therapeutic
mAb can also induce active signals that alter cellular fates. Binding of the T cell receptor
(TCR)-CD3 complex by teplizumab (MGA031; MacroGenics/Eli Lilly) can induce an
altered pattern of cytokine production favoring IL-10 rather than interferon-γ (IFN-γ)
expression. Hence, this mAb modulate T cell function by altering T cells from an
activating phenotype to potentially a tolerizing phenotype.[1, 2, 14] Besides CD20 and CD3,
there are hundreds of surface molecules identified for leukocytes, numbered to 350 for
humans most recently.[15] These molecules are not merely markers on the cell surface to
6

define leukocytes; they also play an important role in cell activities, such as acting as
receptors. Therefore, these molecules are critical because both innate immunity and
adaptive immune responses depend upon the activity of leukocytes. Currently, half of the
24 therapeutic antibodies on the market target surface molecules of leukocytes.

[1, 2]

It

remains to be a huge pool of new targets to generate mAb as effective treatments for
diseases.
The prowess of mAb lies in their specificity and high affinity towards cognate target
molecules. When given intravenously (i.v.), however, these two features are inevitably
diluted. Specificity is diminished when all leukocytes are affected when the drug is
intended in only a subset T cells participating in the disease. Affinity is overshadowed
when only a small concentration of the i.v.-infused mAb reached the target cells. New
strategies overcoming these limitations would make possible the full realization of mAb‟s
therapeutic potential.
A simple way to enhance the binding strength of antibodies is the strategy of
multivalency. An antibody‟s affinity is defined as the strength of the binding to its
cognate antigen. Affinity is typically quantified by the dissociation constant, Kd, of an
individual epitope (of the antigen) from an individual antibody-binding site. [4, 16, 17]

AgAbAgAb



Kd 

[Ag][Ab]
[Ag Ab]

Equation. 2-1

This specific energetic relationship between one antibody binding-site and its

complementary antigenic determinant is described by the “intrinsic” affinity. This is the
7

affinity that is displayed by a monovalent fragment, and it also describes any binding of
either monovalent or multivalent immunoglobulin to soluble, identical, monomeric
antigens.[16-18] In case of polymeric antigens or surface antigens, such as receptors
distributed on a cell surface, the measured affinity can be considerably enhanced by the
formation of multiple binding interactions. The term “avidity”, or “functional affinity”
was then introduced to describe the enhancement of binding strength by multivalency.[1618]

Although avidity is the accumulated strength of multiple affinities summed up from

multiple binding interactions, it is usually more than the sum of the individual affinities
quantitatively. Single-chain antibody fragments (scFv) are comprised of individual
antigen-recognition sites from a mAb and have proven to be a very useful tool for
investigating the role of affinity and avidity. Through phage display, an anti-human Her2
(also designated as CD340, overexpressed on the surface of breast cancer cells) scFv,
G98A, was generated and the binding affinity was determined as Kd=3.2×10-7 M. G98A
was also successfully expressed as IgG variants, which containing two antigen binding
sites. The Kd (now is avidity for the IgG molecules) was found increased to 5.0×10-10
M.[19] It thus appears that avidity can be modulated exponentially by changing the
valence of the mAb in a given system. A number of quantitative approaches for
multivalency have been developed. Diabodies, triabodies, and even tetrabodies were
designed from examples of scFv molecules and applied in virus and cancer targeting.[1921]

However, the gain contributed by the second binding site is only observed if the

antigen is on a surface or is polymeric.[18] Hence multivalent design is not an applicable
strategy for mAb targeting to soluble cytokines. While the multi-expression of surface
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molecules on T cells make it possible to improve the functional affinity of corresponding
mAb through multivalency.
Based on the theory described above, the conceptual innovation of this research is to
exploit antibody clustering to capture T cells. A composite material consisting of two
peptides, EAK and EAKH6, was developed for this purpose. EAK is an amphiphilic
peptide, which self-assembles to form a β-strand-based macroscopic structure upon
injection.[10] EAKH6 is designed to provide H6 domains extending out as mounting sites
when the rest of the peptide is intercalated into the β-strands. With this design, mAb can
be immobilized onto the EAK-EAKH6 composite using an adaptor (protein A/G
complexed withanti-H6 antibody). In contrast to soluble antibodies operating
independently from one another, this composite serves to congregate a collection of
antibody molecules displayed in the same orientation. Once the first antigen has reached
the binding site, the whole cell experiences a reduction in mobility, the other antigens
being restricted to the neighborhood for a second antibody to establish an additional
connection.[18, 22] In these multiple interactions, rebinding can occur when one antigen
dissociates.[20] After complete adsorption has occurred, several surface antigens have to
leave simultaneously before the whole cell is desorbed, thereby make the process
irreversible.[23] The increased in avidity makes it extremely difficult for the target cell to
dissociate (figure 2-1), unless the composite disintegrate. Cells interacting with the
antibodies cannot digest the structure when the size of the peptide assembly (mm)
exceeds the limit of endocytosis.[24] The theoretical justification for this is that when
soluble antibodies bind to cell surface antigens, the decrease in disorderness (-ΔS) in the
system must compensate by enthalpic changes (ΔH), namely electrostatic interactions at
9

the antigen-antibody interface (figure 2-1 a). However, if multiple antibody molecules
were immobilized on a surface in a defined area, there should be small or no net change
in entropy upon binding to antigens. In this scenario the enthalpic change would
dominate Ab-Ag association. Thus the design is underpinned by thermodynamic
considerations.
Additionally, the injectable and self-assembling properties of EAK render the system
described above a local delivery strategy at the pathological sites for mAb. Intravenous
injection is often incapable of delivering functional mAb or their fragments to the target
tissue, as many mAb are degraded in the blood, are captured by receptors and nonspecific binding sites. Furthermore, systemic administration of mAb is always
accompanied with severe adverse effects, especially for those leukocytes-targeted mAb.
Examples include teplizumab (anti-CD3 mAb), which inhibits acute allograft rejection by
T-cell depletion, increases the risk of infection and cancer.[25] Inhibition of CTLA-4 in
patients using ipilimumab represents a new and promising strategy to induce tumor
regression. However, immune-related adverse events (IRAEs) such as rash, colitis and
hepatitis are also observed.[26] Collectively, local rather than systemic delivery may be the
preferred route of mAb delivery to modulate the immunity of host.
Our long-term goal is to modulate immunity locally at the pathological sites. The
studies presented justify the utility of self-assembling peptides as a platform to display a
collection of mAb. The concept of enhanced binding strength through multivalency
(avidity) is applicable by placing multiple antigen-binding moieties in a close physical
proximity (“clustering”). The described experiments suggest the possibility to engage

10

specific subset T cells via immobilized surface molecule-targeted mAb. This prospect
might lead to new treatments using mAb with higher specificity and binding strength.

11

Figure 2-1: Schematic of affinity and avidity of antigen-antibody binding. (a)
individual antibodies, (b) a collection of antibodies immobilized on a surface.
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CHAPTER 3
LITERATURE REIVEW
T CELLS IN HEALTH AND DISEASES
Cells in immune system
The immune system in vertebrates encompasses components and processes that
collectively mitigate and limit harmful effects of pathogens through elimination or
neutralization. Macrophages and neutrophils of the innate immune system provide a first
line of defense against many common microorganisms and are essential for the control of
common infections. However, this defense depends on invariant receptors recognizing
common features of pathogens, which can be overcome by mutational structural changes.
Lymphocytes in the adaptive immune system have provided a more versatile means of
defense with the capability of memory by which subsequent infection by the same
pathogens can be arrested early on.
Adaptive immune responses depend upon lymphocytes, of which there are two major
types: B cells and T cells. Both B and T lymphocytes originate in the bone marrow, but
only the B lymphocytes mature there; the precursor T lymphocytes migrate to the thymus
to undergo their maturation. The sole effector function of B cells is to produce
immunoglobulin as defense against pathogens in the extracellular fluids. This antibodymediated response, also known as humoral immunity, is not effective against intracellular
pathogens such as parasites and viruses, or genetically transformed cells like tumors.
Coordination of T and B cells responses are required to mount effective immunity.
13

T cell activation and differentiation
Once matured in the thymus, T cells leave and remain recirculating between blood and
peripheral lymphoid tissue. Naive T cells, those that have not yet encountered their
cognate antigens, remain resting until being stimulated by antigen-presenting cells
(APCs). APCs engage naive T cells‟ antigen recognition receptor (or T-cell receptor;
TCR) through major histocompatibility complex (MHC) molecules in which antigen
fragments (peptides) are presented. This specific interaction requires augmentation by a
second signal, or co-stimulation, figure 3-1. Effector T cells fall into two major functional
classes distinguished by the expression of the cell-surface proteins CD4 and CD8.
Peptides from intracellular pathogens that multiply in the cytoplasm are carried to the cell
surface by MHC class I molecules and presented to CD8 T cells. They then differentiate
into cytotoxic T cells that kill infected target cells. Peptide antigens from pathogens
multiplying in intracellular vesicles and those derived from ingested extracellular bacteria
and toxins, are carried to the cell surface by MHC class II molecules and presented to
CD4 T cells. They then differentiate into helper T cells that activate other cells such as B
cells and macrophages.
Only dendrtic cells (DCs), macrophages, and B cells are able to express MHC
molecules as well as the co-stimulatory cell-surface molecules (B7 molecules). The
receptor for B7 molecules on the T cell is CD28. Ligation of CD28 by B7 molecules is
absolutely required for the clonal expansion of naive T cells and their differentiation into
armed effector T cells. The most potent activators of naive T cells are DCs, and they are
thought to maintain T cell homeostasis in vivo. Precursor or immature DCs take up
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Figure 3-1: Activation of naive T cells requires two independent signals. (a)
The binding of the peptide: MHC-II complex of APCs to the TCR:CD4 complex of
T cells results in a signal (signal 1) to the T cell that antigen has been recognized.
Activation of naive T cells requires a second “co-stimulatory” signal (signal 2) that
is provided by (b) the binding of the T cell CD28 receptor to the APC B7 molecule.
(c) An APC will neither activate nor inactivate a T cell if the appropriate antigen is
nor present on the APC surface, even if it expresses a co-stimulatory molecule
and can deliver signal 2. However, when a T cell recognizes antigen in the
absence of co-stimulatory molecules, it receives signal 1 alone and is
inactivated.[4] Reprinted with permission from ©2005 Garlan Science Publishing:
[Immunobiology] (6th edition, page 328,339).
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antigens by phagocytosis and macropinocytosis at inflammatory locales and subsequently
migrate to draining lymph nodes. Therein DCs engage T cells flux from tissues
continually. Dual fulfilment of MHC-TCR and co-stimulation leads to activation of T
cells. This stringent requirement serves to minimize T cells from responding to selfantigens expressed in normal tissues, which lack co-stimulatory activities. Antigen
recognition in the absence of co-stimulation inactivates naïve T cells, inducing a state
known as anergy, in which proliferation and differentiation are prevented, figure 3-1 c.
Subsets of helper T cells
CD4+ helper T cells regulate immune responses via the production of soluble factors
that instruct other cellular elements of the immune system. The first well-defined helper
T cell subsets are TH1 and TH2 by Mosmann and Coffman in 1986.[27] TH1 effector cells
are characterized by production of IFN-γ, and are thought to be responsible for activating
macrophages and enabling them to kill intracellular and ingested pathogens. TH1 cells
also produce IL-2, which is required for the proliferation of CD8 T cells. TH2 cells are
defined by production of IL-4 as well as the related cytokine, IL-13. TH2 cells are
considered the classical helper T cells providing help to B cells to generate classswitched antibodies. Indeed, when TH2 cells are preferentially induced, the main response
is humoral immunity. Generally speaking, exposure to IL-4, IL-5, IL-9, IL-10, and IL-13
favors the development of TH2, whereas IL-12 and IFN-γ favor TH1 cell development.[2830]

In 2005, the IL-17 producing cells, named TH17, were classified as a new subset of

CD4+ helper T cells.[31, 32] Activation of precursor T helper cells in the presence of TGFβ and IL-6 is thought to drive differentiation of TH17 cells. TH17 cells are thought to be
particularly important in maintaining barrier immunity at mucosal surfaces, such as the
16

gut and lungs, as well as the skin. Consistent with this, TH17 cells are highly prevalent in
the mucosal tissues of healthy individuals. The fourth main subset of CD4+ T cells is
regulatory T cells (Treg cells), characterized by expression of the transcription factor
Foxp3. Treg cells can emerge directly from the thymus or induced in the periphery from
naive CD4+ T cells through TGF-β.[29, 33]
Many diseases can be characterized as an abnormal change in the polarization of T cells.
For example, in AIDS patients, HIV infection initiates a rapid and substantial decline in
CD4+ T cells. [34] In inflammatory allergic reactions, for example, asthma, are associated
with the production of IgE antibodies against common, innocuous antigens. IgE antibody
production requires TH2 cells that produce IL-4 and IL-13, and it can be inhibited by TH1
cells. The presentation of low does of antigen can favor the activation of TH2 cells over
TH1 cells, and many common allergens are delivered to the respiratory mucosa by the
inhalation of a low dose. On the other hand, delayed-type hypersensitivity reactions, e.g.,
insect venom caused local skin swelling and erythema, are mediated by TH1 cells and
CD8 cytotoxic T cells.[4, 35] Beyond the TH1 and TH2 subsets, TH17 cell have recently
been identified as important in the response to pulmonary and colonic bacterial
infections.[36, 37] Commensal gut floras contribute to the expansion of TH17 cells, leading
to inflammatory bowl diseases (IBD). IL-17 mRNA has been also found to be highly
expressed in inflamed mucosa from IBD patients. More recently, it has been shown that
TH17 cells present in tumors.[38] While the cause-effect relationship between TH17 cells
operating in tumors has been controversial. Evidence is accumulating to suggest that
TH17 cells can promote protective antitumor immune response.
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Regulatory T cells
Deficiency of Treg cells (in frequency or functions) can result in severe autoimmune
syndromes, such as massive lymphatic proliferation, diabetes and enteropathy.[39]
Conversely, an increased level of Tregs often occurs in malignancies, allowing the
tumors to circumvent host immune attacks.[40,

41]

First described in the 1970s as

“suppressive T cells”, this elusive subset is now named “regulatory T cells” with much
renewed interest.[39,

40, 42, 43]

In 1995, Sakaguchi and coworkers showed that the

interleukin-2 (IL-2) receptor α-chain, CD25, is constitutively overexpressed on CD4+
regulatory T cells. These CD4+CD25+ cells constitute approximately 10% of the total
peripheral CD4+ T cells. It is now generally accepted that this subset contributes to the
maintenance of self-tolerance by down-regulating immune responses to both self and
non-self antigens in an antigen specific and non-specific manner. [44]
Treg cells have been extensively studied in a variety of physiological and pathological
conditions in mouse and man. The data support the fact that Treg cells suppress
responder (CD8+) T cells and myeloid cells by secreting suppressive cytokines (e.g., IL10, TGF-β), competitively consuming IL-2, and inducing cytolysis. It has also been
found that Treg cells can suppress the function APCs and thus indirectly block the
activation of T cells.[45] This latter mode of action has been attributed to the action of
cytotoxic T lymphocyte-4 (CTLA-4), a membrane-bound competitor of CD28 for B7
molecules on APC. CTLA-4 binds B7 molecules about 20 times more avidly than does
CD28 and delivers an inhibitory signal to the activated T cell.[46] Efficacy of mAb
blocking this negative co-stimulator has been demonstrated in mouse models of various
tumors and are being evaluated in phase III clinical trials. .[47]
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It has been postulated that Treg cell-mediated immunosuppression promotes tumor
growth by changing the functions of CD8+ cytotoxic T cells and NK cells operating in
tumors.

[40, 42, 48, 49]

It has been suggested as a factor to explain the sub-optimal clinical

responses of active tumor immunotherapy, including various formats of vaccines.[48] Data
from Valzasina et al.‟s work demonstrate that the number of CD4+CD25+ T cells has
been increased in draining lymph nodes and the spleen of tumor-bearing mice. In that
study, about 10-15% of CD4+ T cells were found bearing the CD25 marker in draining
lymph nodes and the spleen of tumor-free mice. Whereas this level increased to 22-30%,
even to 40% as the highest in tumor-bearing mice.[41] Thereafter, a higher frequency of
Treg cells in peripheral blood was reported in patients with various cancers including
non-small-cell lung cancer, breast cancer, ovarian cancer, pancreatic cancer, etc. These
studies demonstrated that peripheral Treg cells possess suppressive activities thereby
comprise anti-tumor immunity in cancer patients.[40, 49-52]
Based on these results, it was predicted that removal of Treg cells from tumors and
tumor-draining lymph nodes would unveil a strong antitumor immunity. Monoclonal
antibodies targeting to the surface molecules of Tregs have been found, in some cases, to
reverse Treg-dependent tumor immune-tolerance.[40, 42] In vivo administration of CD4 or
CD25-specific antibodies have been found to induce effective tumor rejection in murine
tumor models. Concomitantly, dramatic increases of CD8+ T cells and INF-γ production
were detected inside the tumor after CD4+ T cell depletion.

[6, 53]

In the study done by

Coe et al. demonstrated that Treg cells constitutively expressed higher level of
glucocorticoid-induced tumor necrosis factor receptor (GITR), a member of the TNF
receptor family, than conventional T cells. A single injection of DTA-1 (anti-GITR mAb)
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resulted in the regression of established solid tumors. It was also showed that the
regression of tumor by anti-GITR mAb therapy was correlated with increased
accumulation of tumor-infiltrating CD4+ (17% compared to 3% in untreated group) and
CD8+ (22% compared to 4% in untreated group), but decreased accumulation of Treg
cells (0.4% compared to 1.2% in untreated group).[54]
Several of the mAb are on the market, for example daclizumab (Roche), a CD25specific agent, and tremelimumab (Pfizer) and ipilimumab (Bristol-Myers Squibb),
CTLA4-specific agents.[2] These antibody-based treatments have been proved to be
effective to enhance adaptive immunity and promote tumor regression. However, clinical
outcomes are limited by nonspecific depletion of effector T cells, and in many cases,
systemic autoimmune side effects. Thus these antibody-based approaches are limited.
Moreover, the tumor mass is not amenable to the penetration, distribution and
accumulation of antibodies. It is acidic (pH~6), increasing the likelihood of antibody
denaturation. The elevated pressure (due to microvascular hypertension) resulting from
extravasated fluids causes an outward convective current, moving macromolecules out of
the tumor.[55] Collectively these factors call for new strategies in using anti-T cell
antibodies. The ability to capture CD4+ T cells and alter their phenotypes in vivo could
be developed into a new type of immunotherapy.

20

BETA STRUCTURE-BASED SELF-ASSEMBLING PEPTIDE SCAFFOLDS
In the past decade, many studies have focused on the design and use of self-assembling
peptides as biological scaffolds. These peptides share a common feature of selfassociation in aqueous solutions. They are either fragments of natural proteins or derived
by de novo biomolecular design. Within the biomaterials community, molecular selfassembly is, defined as spontaneous organization of molecules under near
thermodynamic equilibrium conditions into structurally well-defined and stable
arrangements through noncovalent interactions.[56] Such interactions typically include
hydrogen bonding, electrostatic and van der Waals interactions. The first member of the
family which has the sequence Ac-(AEAEAKAK)2-NH2, commonly referred to as
“EAK16” or “EAK-II”, (now termed “EAK” here), was discovered in the yeast Z-DNA
binding protein Zuotin.[9,

10]

EAK contains repeats of alternating polar and nonpolar

residues and repetitive pattern of positive and negative charges (figure 3-2 a). These
physical properties provide the mechanisms for intermolecular complementarities of
hydrophobic and ionic interactions.
Proposed self-assembly mechanism
EAK contains tandem repeats of alternating hydrophilic and hydrophobic residues, in
which every other residue in the peptide is alanine. At neutral pH, the four glutamic acids
and four lysines are negatively and positively charged, respectively. In deionized or low
ionic water, EAK forms stable β-sheets in which the polar and non-polar side chains
orient to opposite sides (figure 3-2 b). Resulting is a structure in which the charged side
chains lie on the same side and all alanine side chains are oriented on the opposite side.
Upon exposure to salt solution, these amphiphilic β-sheets spontaneously stack up by
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inter-strand pairing of charged residues (glutamate and lysine) and hydrophobic
interactions of alanines (figure 3-2 c).[10,

57-59]

Stacks of fibrous oligomers (7-20 in

diameter) interweave to form macroscopic membrane-like structures (figure 3-2 d and
e).[10,

57]

Once formed, these macroscopic structures acid and protease-resistant, and

remains intact at temperature up to 90°C.[11]
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Figure 3-2: Schematic structures of EAK and EAK nano-structure. (a)
chemical structure of EAK, (b) a single β-sheet formed from two molecules of
EAK16, (c) a perpendicular staggered β-sheets, (d) stacking of β-sheets. The
staggered peptides are oriented along the x axis. The z axis has the
complementary ionic bonds between lysine and glutamic acid, as well as the
hydrophobic bonds between alanines. The y axis contains the conventional βsheet hydrogen bonds.[10] (e) nanofibers cross-linked to form the membrane.
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Salt effect on the self-assembly
Zhang and coworkers further studied the effects of salts on the spontaneous-assembly
process.[10, 56] It was observed that only monovalent cations are most effective in inducing
assembly formation. The order of effectiveness has been determined as Li+>Na+>K+>Cs+,
which is consistent with the hydrated radius of the ions: 3.4Å (Li2+), 2.8Å (Na+), 2.3Å
(K+) and 2.3Å (Cs+). Divalent cations on the other hand induce disordered aggregation,
rather than ordered periodic structures. NH4+ and TrisHCl are not able to induce EAK
to form aggregates. It is an indication that the metal ions are more likely the components
of the peptide structure, rather than as a catalyst only stabilizing the electronic charges.
The salt-induced process is thought to be driven by charge screening by monovalent
cations between the basic and acidic side chains on peptide molecules, resulting in
decreased electrostatic repulsion. This however does not explain the differential effects of
monovalent and divalent ions. A unifying perspective is that the spontaneous process is
driven by free energy gained from entropic release of water molecules structured around
the alanines into the bulk solution as two β-sheet stack upon one another at high
concentrations.[60] When multiplied throughout many alanines in the system a significant
amount of energy can be derived, making the process a spontaneous one. In this scenario
the charged side chains reduce the entropic gain in free energy by decreasing the
orderness of bound waters around alanines. The addition of monovalent and small ionic
species dislodges the charged side chains from the alanine salvation spheres thereby
allowing maximal orderness of water molecules surrounding the hydrophobic moieties.[61]
The precise role of salts, however, remains under investigation.
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Concentration effect on the self-assembly
Both Fung et al.[62] and Hong et al.[63] reported that there is a critical self-assembly
concentration (CSAC), which is 0.1mg/ml (60μM) for EAK in pure water. Surface
tension and self-assembled nanostructures formation were determined for a wide range of
peptide concentrations using an axisymmetric drop shape analysis-profile (ADAS-P) and
atomic force microscopy (AFM). The principle of the analysis was that changes in
solution properties associated with molecular aggregation could be measured. A “break
point”, or minimum, is observable in the surface tension corresponding to the CSAC.
AFM studies revealed that EAK formed fibrillar networks above the CSAC, while
isolated filaments were observed at concentrations below the CSAC. The implication of
these results is that mechanical properties of the assembly can be tuned by varying the
concentration of the peptides in the system.
pH effect on the self-assembly
While interactions among the charged amino acids in EAK may not initiate stacking of
β-sheets, they must contribute to the stability of the insoluble structures through
electrostatic interactions. The ionization state of the four lysines and four glutamic acids
in EAK can be tuned by pH in the environment, with all ionized at neutral pH. EAK
contains four positively charged lysine and four negatively charged glutamic acid
residues at neutral pH. In the aqueous environment, lysine has an estimated pKa of 10
and glutamic acid has an estimated pKa 4.4, with EAK having a calculated isoelectric
point (pI) of 6.7. It was predicted that changes in pH would greatly affect the β-sheet
structure of EAK. These effects have been studied systematically. Using circular
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dichroism (CD), Zhang et al. reported a stable β-sheet structure for EAK from pH 1.5 to
11.[11] AFM images of EAK at various pH values indicated fibrillar nanostructures
formed throughout the pH range from 4 to 11.[64] Given the purported configuration of
the self-assembly, it is unexpected that no significant changes of EAK structures were
registered. Such resistance to acidic and alkaline conditions is likely due to the
complementary ionic bonds or hydrogen bonds between glutamic acid and lysine when
EAK exists in the β-sheet form. Protonated and deprotonated carboxylic acids and amines
may remain hydrogen bonded. Since the β-sheets are staggered and overlaid, the
collective interaction energy should be much greater in for individual β-sheets. The
additive interactions within the multilayer aggregate most likely cause the unusual
stability.[56, 64]
Design rationale for self-assembling peptides
The sequence dependence of self-assembling peptides motivated the design of novel
structures by changing the amino acid compositions. Assumed to be relatively low in
immunogenicity and good biocompatibility, such sequences have been used mainly as
scaffolds for tissue engineering in regenerative medicine and controlled drug release
systems. Among these are peptides that are classified based on ionic complementary
typed moduli (modulus I, modulus II, modulus III, modulus IV, etc., and mixtures
thereof). This classification scheme is based on the pattern of alternating positively and
negatively charged amino acids separated by one, two, three residues, and so on. For
example, charge arrangements for modulus I, modulus II, modulus III, and modulus IV
are − + − + − + − +, − − + + − − + +, − − − + + +, and − − − − + + + +, respectively.[57, 58]
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Therefore, the first EAK peptide with the sequence Ac-(AEAEAKAK)2-NH2 is termed as
EAK16-II.
Xiong et al. claimed that in self-assembling oligomeric peptides the polar/nonpolar
periodicity could overwhelm the intrinsic propensities of amino acid residues, serving as
the major determinant of peptide secondary structure.[65] Extending this notion, Zhang et
al. hypothesized that if the charged residues in EAK are substituted with other amino
acids with the same charge (i.e., Glu−>Asp or Lys−>Arg in the reversed EAK sequence)
or hydrophobic residues with other hydrophobic amino acids (Ala−> Phe or Ala−> Leu),
there would be essentially no drastic effects on the self-assembly process. [65, 66]
To test this hypothesis, another set of self-assembling peptides containing the RAD
sequence, a similar motif found in EAK was characterized. These include RAD16-I, Ac(RADARADA)2-NH2, and RAD16-II, Ac-(RARADADA)2-NH2. Indeed, RAD16-I has
been comercially produced as PuraMatrix from BD Biosciences (MA, USA). [67]
Application of RAD16-I in controlled drug release
Because of the small diameter of peptide nanofibers (~10nm), nanofibers gels have a
high surface:volume ratio compared to biopolymers with larger diameter fibers. This high
surface ratio permits the adsorption of large quantities of drugs. [68]
Zhang et al. examined RAD16-I as matrices for controlled drug release. Microscopic
images revealed that the peptide self-organizes into interwoven nanofibers with diameters
of 10-20nm. These nanofibers further associate to form highly hydrated hydrogels (up to
99.5% w/v water), with pore size between 5 and 200 nm in diameter.[57, 69] The group
reported that RAD16-I can be used to control the release of small molecules. Phenol red,
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bromophenol blue, 8-hydroxypyrene-1,3,6-trisulfonic acid trisodium salt (pyranine, 3PSA), 1,3,6,8-pyrenetetrasulfonic acid tetrasodium salt (4-PSA), and Coomassie Brilliant
Blue G-250 (CBBG)) (figure 3-3) released through 5% w/v RAD16-I hydrogels were
investigated. The mass-transfer kinetics for the release of the dyes were illustrated with
mass released fraction (Mt/M∞) monitored as a function of time (t). Phenol red, which is
presumed to have no electrostatic interactions with the peptidic nanofibers, was released
quickly; more than 50% of the loaded amount was released after 2 h and reached a
plateau after 12 h. Although bromophenol blue has molecular structure similar to phenol
red, it is not readily released from the matrices. Bromophenol blue has a lower pKa (4)
than phenol red, which has a pKa of 7.9. Hence, the phenolic hydroxyl group of
bromophenol blue tends to dissociate at neutral pH and thereby can interact strongly with
the positively charged amines of the arginine residues in RAD16-I. Even after 7 days,
bromophenol blue was essentially retained in the peptide scaffold. The mass fraction
(Mt/M∞) of release for 3-PSA and 4-PSA reached 26% and 9% after 7 days, respectively.
Additionally, the diffusivity of 3-PSA was approximately seven times higher than that of
4-PSA. The difference in the release rate is most likely due to electrostatic interactions
between the sulfonic acid groups and the positively charged amine groups of the peptide
nanofibers. 4-PSA has 4 sulfonic side groups while 3-PSA only has 3. As CBBG binds
strongly to proteins, it is concluded that this interaction impedes its release from the
RAD16-I matrices. [69]
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Figure 3-3: Molecular structure of the model drugs: (a) phenol red, (b)
bromophenol blue, (c) 8-hydroxypyrene-1,3,6-trisulfonic acid trisodium salt (3PSA), (d) 1,3,6,8-pyrenetetrasulfonic acid tetrasodium salt (4-PSA) and (e)
Coomassie Brilliant Blue G-250 (CBBG).[69] Reprinted, with permission, from ©
2006 Elsevier B. V.: [Journal of Controlled Release] (Vol.115 Page19, 2006).
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Subsequently, the same group tested a series of proteins as model encapsulated drugs
to study the kinetics of release from RAD16-I peptide hydrogel.[70] These include
lysozyme, trypsin inhibitor, bovine serum albumin, and IgG, proteins with differing
physicochemical

properties

(pI

4.6-11.4;

molecular

mass,

14.3-150kDa)

and

morphologies (listed in Table 3-1). The results showed that the peptidic matrix appeared
to be a robust system for sustained release of proteins in aqueous environments. IgG has
the slowest release among the proteins tested, with measurable concentration detectable
only after 60 h. As expected, it was found that large proteins were retained inside the
matrix for longer periods compared to smaller proteins, as in the case for most other
fibrous matrices.[68] The implication being that the rate of release is more sensitive to
physical size than charge. Lysozyme, the smallest (radius ~1.9nm) among the proteins
studied, was released fastest. Trypsin inhibitor, which is slightly larger and oppositely
charged compared to lysozyme, was released slower than lysozyme but faster than bovine
serum albumin, a larger protein. Conversely, the release rates do not correlate with the
isoelectric points of the proteins. The data also indicate that increasing the peptide
concentration results in a higher density of nanofibers in the network, which could hinder
the release of the proteins. Therefore, protein release through the RAD16-I can be
controlled by varying the peptide concentration. In examining the functionality of the
protein released, identical circular dichroism (CD) spectra and similar activity values
were obtained for proteins recovered compared to the freshly prepared native proteins.
Hence, it can be concluded that the encapsulation process and release mechanisms do not
affect integrity of the proteins studied.
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Protein

Molecular mass

Hydrodynamic radius

pI

( kDa)

(nm)

Lysozyme

14.3

1.9

11.4

Trypsin inhibitor

20.1

2.4

4.6

BSA

66.0

3.6

5.3

IgG

≈150.0

5.3

≈7.2

Table 3-1: Physicochemical properties and morphologies of the model
proteins.[70]
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Immunogenicity of RAD and EAK peptides
Zhang et al. attempted to produce antibodies using RAD16-II and EAK oligopeptides.
However, when these peptides were either alone or conjugated with other proteins and
injected into rabbits, they did not elicit a detectable immune response, and no significant
titers of antibodies were obtained.[61] It was found that these peptides had a similar amino
acid sequence as a segment in intermediate neural filament H, L and M proteins.[71] These
sequence similarities may cause the lack of immunogenicity. Holmes et al. injected EAK
and RAD (including RAD16-I and RAD16-II) peptides into the rats leg muscles to test
for their induction of inflammation. The rats were killed 9 days or 5 weeks after the
injections. The entire muscle was dissected and sectioned. The muscle sections were then
stained with Nissl and thionin (specific for ribosomal RNA) and examined by using light
microscopy for mononuclear cell infiltration and muscle fiber necrosis for signs of
inflammation or necrosis. No apparent inflammation or any structural abnormalities were
observed in the muscles that were injected with either saline or the peptides.[12] A
collection of these results indicates that these self-assembling peptides are nonimmunogenic, which is important so as to reduce immune rejection if these peptides are
developed for tissue engineering or in vivo drug delivery.
In vivo application of RAD16-II in protein delivery
Lee et al. have investigated RAD16-II for myocardial protein delivery.

[68, 72-74]

In one

application, platelet-derived growth factor (PDGF) was bound to RAD16-II noncovalently and resulted sustained delivery (~2 weeks) of the growth factor when the
construct was injected into infarcted rat myocardium. After myocardial infarction, this
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local protein therapy improved cardiac function, decreased cardiomyocyte apoptosis, and
decreased infarct size.[72] This group also attached biotin to RAD16-II, and formed the
biotinylated hydrogel by using 1:100 biotinylated peptides/nonbiotinylated peptides.
Insulin-like growth factor 1(IGF-1) was then biotinylated as well and tethered to the
peptide hydrogel with the aid of tetravalent strepavidin (figure 3-4). IGF-1 is a small
protein that diffuses readily through tissues, a property that allows it to signal over great
distances, but could restrict its retention within a tissue for prolonged periods. This biotin
sandwich method is designed to deliver IGF-1 with biotinylated peptides to maximize the
probability of peptide self-assembly and thus retention in the myocardium. After injection
into rat myocardium, this “biotin sandwich” approach provided sustained IGF-1 delivery
for 28 days, compared to 3 days for untethered IGF-1.[73] In order to incorporate protein
stably into nanofibes, fusion protein was also made. For instance, this group constructed a
fusion protein consisting of the stromal cell-derived factor-1 (SDF-1) sequence and the
RAD16-II sequence, referred as SDF-1-RAD. SDF-1 is a potent chemoattractant for
endothelial progenitor cells. Injected with a mixture of RAD16-II and SDF-1-RAD, the
infarcted zone showed improved cardiac function and capillary density. [74]
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Figure 3-4: Schematic showing the biotin sandwich method: Tethering
biotinylated IGF-1 (b-IGF) to biotinylated self-assembling peptides by using
tetravalent strepavidin.[73] Reprinted with permission from ©2006 The National
Academy of Science of the USA: [PNAS](Vol.103 Page 8156, 2006).
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Design of KLD12 and its application in cell culture
In addition to the classical 16-mer peptides, smaller self-assembling sequences,
including KLD12, Ac-(KLDL)3-NH2, have also been designed and tested.[75] Recall that
the principal forces of the self-assembly are ionic complementary and hydrophobic
interactions. It was subsequently determined that the proportion of hydrophobic residues
in the sequence significantly influences the mechanical properties of the scaffolds and the
speed of self-assembly[75]. The more hydrophobic the sequence, the shorter the length is
required for aggregate formation with stronger mechanical properties. KLD12 was thus
designed on the basis that leucine is more hydrophobic than alanine, and therefore more
likely to pack tightly in the nanofibers in aqueous conditions, resulting in higher
mechanical strengths.[75, 76] Grodzinsky et al. characterized KLD12 as a 3D scaffold for
encapsulation of cells. Chondrocytes seeded within the KLD12-I matrix retained their
morphology. The cell-peptide composite developed a cartilage-like extracellular matrix
(ECM) rich in proteoglycans and type II collagen, indicative of a stable of chondrocyte
phenotype. The results demonstrated the potential of KLD12-I as a scaffold for the
synthesis and accumulation of a cartilage-like ECM within a three-dimensional call
culture for cartilage tissue repair.[76] This peptide was also tested with bone marrow
stromal cells (BMSCs). Only cells seeded with the peptide matrix but not agarose yielded
high glycosaminoglcan content, spatially uniform proteglycan and collagen type II
deposition (all indicating for cell proliferation).[77]
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Design and application of β-hairpin peptides
Another configuration for assembly is a design through β-hairpin. In this conformation
two adjacent strands in an oligopeptide oriented in an antiparallel arrangement are linked
by a short loop of two or five amino acids, shaped as a hairpin. Schneider and Pochan
have developed a set of β-hairpin peptides that self-assemble into rigid hydrogels.[78-84]
These peptides contain a pair of turn inducing residues such as proline followed by
glycine or threonin. The cyclic structure of proline causes a slight kink in the α-carbon
backbone and in combination with the more comformationally flexible glycine or
threonine residues that follow allows a complete reversal of the direction of the α-carbon
backbone. The loop is cemented by the two residues before and after the turn-inducing
pair and subsequent residues to hydrogen bond together, holding the peptide strand into a
tight hairpin. Non-natural D form of proline is used in the turn sequence to permanently
force a type II’ turn and prevents a cis-proly bond that could create heterogenicity in the
unfolded population of peptides (figure 3-5 a).[79] A prototype of these is “MAX1” (figure
3-5),[80] which contains a total of 20 amino acids with alternating valine (V) and lysine (K)
residues on two β-strands connected by a tetrapeptide (-VDPPT-) sequence. These
peptides are designed to remain freely soluble and unfolded due to electrostatic
repulsions between the positively charged lysine side chains at neutral pH. When a
physiologiacally relevant salt concentration is introduced, the electrostatic repulsions
between the lysine side chains are screened and the peptide folds into a β-hairpin
structure, stabilized by intramolecular hydrogen bonds. When folded, the hairpin exhibits
facial amphiphilicity and the valine-rich face undergoes hydrophobic collapse, driving
the self-assembly of the folded hairpins into fibrils. The β-hairpin peptidic gels are
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cytocompatible with mammalian cells, including fibroblasts, mesenchymal stem cells,
primary articular chondrocytes, and hepatocytes.[78, 81] Cells can be encapsulated during
self-assembly, resulting in cells being homogeneously distributed throughout the fibrillar
network. In addition, these peptide hydrogels possess the ability to shear thin and recover,
allowing the gel-cell constructs to be delivered via syringe. [78, 82]
The Schneider series and other amphiphilic peptides demonstrate a key feature: it is
possible to tailor matrices to specific biomedical applications through unique
arrangements of secondary structures by careful selection of amino acids. This flexibility
drives the imagination of designing capabilities for self-assembling structures. In addition
to those already discussed, several other systems warrant mentioning. Peptide P11-4 (AcQQRFEWEFEQQ-NH2) was designed by Aggeli et al. to self-assemble to form β-sheets
and nematic gels in the pH range 5-7 at concentrations ≥12.6 mM in water. This selfassembly is reversibly controlled by adjusting the pH of the solvent. A peptide P 11-3 (AcQQRFQWQFQQQ-NH2) whose self-assembly behavior is independent of pH was first
designed. pH control was then incorporated by appropriately positioning glutamate (E)
side chains so that the peptide-peptide free energy of interaction in the tapelike
substructure was strongly influenced by direct electrostatic forces between COO- in
glutamate.[85,

86]

Collier

and

Messersmith

described

a

similar

peptide,

Ac-

QQKFQFQFEQQ-NH2, which exists as β-sheets and self-assembled into fibrillar
aggregates. The resultant structures contain several pendant glutamine residues that can
be cross-linked with lysine containing peptides in the presence of transglutaminase and
calcium ions.[87]
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Figure 3-5: Schematic of β-hairpin peptide assembly. (a) Sequence and
proposed β-hairpin structure of peptide MAX1. Alternate folding/self-assembly
pathways dependent on turn structure contained within MAX1. Valine at position
9 strongly enforces a trans-prolyl amide bond geometry favoring hairpin
formation prior to self-assembly (pathway a). A cisgeometry, which is designed
against, may result in an extended conformation, which could undergo mixed
self-assembly with correctly folded hairpins (pathway b). [79] Reprinted with the
permission from © 2002 American Chemical Society: [Journal of the American
Chemical Society] (Vol. 124, Page15031, 2002) (b) Proposed mechanism for the
folding and self-assembly of β-hairpin hydrogels.[80] Reprinted with the
permission from © 2008 Elsevier Ltd. [Biomaterials] (Vol. 30, Page 1340, 2009).
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Taken together, synthetic self-assembling peptides have tremendous potential as
biomaterials because they can be readily modified at the amino acid level. The responsive
to stimuli, for example ionic strength and pH, is a major advantage in developing in vivo
applications by designing around one or more physiological condition(s). The peptides
appear to be non-immunogenic, and the matrices can be loaded with biologically active
proteins for prolonged release.
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CHAPTER 4
PHYSICAL CHARACTERIZATION OF EAK-EAKH6 COMPOSITE
INTRODUCTION
Both naturally occurring and synthetic materials have been used for protein delivery.
Naturally occurring materials include collagen, gelatin, agarose, alginate, chitosan, etc.
The advantage of naturally occurring materials is their known physiological activities,
mechanical properties, and biodegradability. These materials may also be relatively
inexpensive. However, potential transfer of infectious agents from animals, antigenicity
and unstable material supply are potential disadvantages. Moreover, specific properties of
naturally derived materials that are necessary for protein delivery are difficult to design.
Synthetic polymers can be produced on a large scale, and their structural and mechanical
properties can be more easily modified. Commonly used materials are polylactide (PLA),
glycolide-lactide copolymer (PLGA), polyvinyl alcohol (PVA), and poly-ethylene glycol
(PEG). Potential disadvantages of synthetic polymers are a decrease in local pH from
acid breakdown products, bulk degradation, and inflammatory responses. [68]
In the past decades, self-assembling peptides have been developed for tissue
engineering and protein delivery. These peptides recently attracted intense research
interests because they are injectable, non-immunogenic, biocompatible, and flexible in
design and modification.[56,

57, 88]

The first member of this class of self-assembling

peptides is EAK. Discovered in the sequence of the yeast Z-DNA binding protein zuotin,
EAK (also referred to as “EAK16-II” in the literature) is prototypical of a class of selfassembling peptides characterized by periodic repeats of alternating polar and non-polar
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amino acids. In water, EAK adopts a β-sheet conformation. In buffers containing
monovalent metal ions (Na+, K+), the peptide assembles into an ordered stable quaternary
β-sheet structure. This high molecular weight assembly is resistant to proteases, high
temperature (up to 90°C) and acidic or alkaline conditions (pH 4-11). [9-11]
The EAK assembly has been used as a scaffold for promoting cell growth in vivo.
Cells co-injected with the EAK peptide form cell-embedded matrices with biological
functions. Such applications in tissue engineering represent a form of individualized
medicine mostly practiced in academic settings. An “off-the-shelf” injectable capable of
modulating host cells in vivo would have much wider applications. [58, 61]
The goal of this project is to develop a platform technology by introducing a His-tag
onto the insoluble structure as “mounting sites”. This was done by seeding into the
assembly with EAKH6, which contains six histidines at the C terminus of the EAK
sequence. It was hypothesized that the amphiphilic domain (AEAEAKAK)2 intercalates
into the EAK β-sheets, with the C-terminal his-tag domain extruding out-accessible as
binding sites. The assumption is that the histidine appendage does not interfere with the
ability of the amphiphilic domain to engage the same in EAK oligomers in macroscopic
insoluble structures.
This chapter describes preparation and characterization of assemblies made with EAK
and EAKH6. The goal is to demonstrate the integration of EAKH6 into the EAK -sheet
network using analytical and biochemical means. It provides physical evidence on which
subsequent functionalization is based. Four techniques were used to characterize the
EAK-EAKH6 composite: UV-Vis, circular dichroism (CD), Fourier transformed infrared
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spectroscopy (FTIR) and an enzymatic reaction using nickel-bound horseradish peroxide
(HRP-Ni) as a probe of the H6 domain. Collectively, results from these analyses show
evidence for EAKH6 integration into the EAK network.
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MATERIALS AND METHODS:
Peptide assembly preparation
The peptides EAK and EAKH6 were custom synthesized by EZBiolab (Carmel, IN,
USA) custom synthesis service. The purities of EAK and EAKH6 are 79.54% and
92.72% respectively. The peptides were acetylated at the N-termini and amidated at the
C-termini to be chemically inert. Their identities were confirmed by mass spectroscopy.
Upon arrival, the lyophilized peptides were reconstituted in sterile deionized water (18.2
MΩ at 25°C) at a concentration of 3.13mM (5mg/ml for EAK and 7.8mg/ml for EAKH6)
and stored at -80°C until use. The peptide sequences are showed in figure 4-1.
To form the assembly, the peptides were thawed out. 10-20μl of the stock solution of
EAK, or the mixture of EAK and EAKH6, was injected into 1.0 ml of phosphate buffered
saline (PBS; 154 mM sodium chloride, 5.5 mM sodium phosphate dibasic, 1.2 mM
potassium phosphate monobasic; pH 7.4; no calcium or magnesium). 2-4μl 0.1%(w/v)
Congo red, which is the dye binding to β-sheet specifically, was added to visualize the
structure.
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Figure 4-1: Amino acid sequence of EAK and EAKH6. Peptides are
acetylated and amidated at the termini.
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UV-Vis analysis
The UV absorbance of peptide bond has been determined to investigate how much
percentage of EAKH6 can be incorporated into the EAK fibrillar structure. The samples
were prepared as follows: 10µl of the stock solution of EAK peptide (5mg/ml) was mixed
with 1µl of the stock solution of EAKH6 (7.8mg/ml) peptide. This mixture was added
into 1ml PBS to initiate the structure formation. After that the sample was centrifuged at
16,000×g force for 20 min to spin the peptide assembly down. The supernatant was
collected and absorbance at 205 nm was measured on a Lambda35 UV/Vis Spectrometer
(PerkinElmer Instruments, Shelton, CT, USA). Meanwhile the groups of 50 µg of EAK
and 7.8µg of EAKH6 by themselves were incorporated as well.
Fourier transform infrared spectroscopy spectroscopy
FTIR spectra were recorded on a Thermo Nexus 470 Infrared Spectrometer operated at
a spectral resolution of 0.5 cm-1 over 1024 scans. Fibillar structures were formed in PBS
(1ml) with 100μg EAK, or the same amount of EAK with 78μg EAKH6 for the
composite. After centrifugation (16,000×g for 20min using an Eppendorf 5415R
Centrifuge), the supernatant was removed and the structure was washed to remove
unbound EAKH6. The fibrillar structure collected was then lyophilized by a Labconco
Freeze Dry System/Freezone 4.5 prior to FTIR analysis under inert condition and
scanned over 400-4000 cm-1.
Circular Dichroism (CD) measurement
CD spectra were obtained on a Jasco J-810 spectropolarimeter (Jasco Analytical
Instruments, Germany) with Jasco‟s Spectra ManagerTM software for data processing.
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Spectra were recorded from 190 to 250 nm at room temperature by accumulating 10 runs.
After correction for solution blanks, absorbance values were converted to mean residue
ellipticities according to the equation 4-1:

[] 

100 obs
cnl

Equation. 4-1

Where θobs denotes the measured ellipticity, c the peptide concentration in mM, n the


number of amino acid residues, l the path length of the quartz cuvette in cm. Finally the
θobs was plotted against the wavelength using Excel 2007(Microsoft, USA). The
secondary structure conversion of EAKH6 was evaluated by the comparing the CD
spectra of EAKH6 by itself and the EAKH6 component in the mixture with EAK.
Furthermore, the analysis of secondary structure composition has been performed using
CD Pro software, which contains three popular methods (SELCON3, CONTINLL and
CDSSTR)

for

CD

analysis.

The

software

is

available

at

the

website:

http://lamar.colostate.edu/~sreeram/CDPro/main.html. A reference set containing 43
soluble proteins was chosen to execute the programs.
Nickel conjugated horseradish peroxidase (HRP-Ni) binding assay
HRP-Ni is a nickel (Ni2+) activated derivative of horseradish peroxidase (HRP) used
for direct detection of poly-histidine tagged proteins since nickel can form coordination
interaction with histidine side chains. HRP-Ni was obtained from Pierce (IL, USA) as
lyophilized powder. Upon arrival, the enzyme was reconstituted in sterile ddH2O at a
concentration of 4mg/ml, and stored at -80°C until use.
The peptide assembly was formed by injecting a mixture of 50μg EAK and 19.5μg
EAKH6, mole ratio 1:4 (EAKH6: EAK), into 1ml PBS. The groups of individual 50μg
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EAK and 19.5 μg EAKH6, and equal volume of PBS were included as well. 1μl of
0.1%(w/v) Congo red was also added to visualize the structure. After the membrane-like
structure was formed, 1μl of 0.8μg/ml (1:5,000 dilution of the stock) HRP-Ni was added
into each sample. The mixtures were incubated on ice for 1 hour. Then the samples were
centrifuged at 16,000×g for 20 min to spin the assembly down. The supernatants were
taken out and filtered through a 0.22μm filtered to remove any insoluble fragments. 100μl
of the filtrate was mixed with 100μl of TMB substrate (BD Biosciences, CA, USA) in
96-well plate. Triplicates were done for each sample. The plate was incubated for 30
minutes at room temperature in the dark. Afterwards, 50μl stop solution (2N H2SO4) was
added to each well, and the plate was read for absorbance at 450nm. The results were
corrected by subtraction of the absorbance at 570nm. All the absorbance was determined
using a PerkinElmer wallac 1420 multilabel counter (PerkinElmer Life and Analytical
Sciences, Finland). A standard curve of HRP-Ni was also performed from serial dilution
of 0.125ng/ml to 8ng/ml. The concentrations of unbound HRP-Ni in the supernatants
were then calculated.
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RESULTS AND DISCUSSION:
Peptide assembly
EAK assembly can be prepared and visualized by injecting 10μl of the stock peptide
solution (5mg/ml) mixed with 2μl 0.1% (w/v) Congo red into 1ml PBS. The insoluble
structure is red, due to the binding of Congo red purported to bind to hydrophobic
grooves in fibrous -sheet structures (figure 4-2 a).[10,

89]

Figure 4-2c shows the self-

supporting nature of the assembly prepared by mixing equal volume of EAK (5mg/ml)
and PBS. This suggests that the peptide molecules assemble into a 3-dimensional
structure.
EAK-EAKH6 assembly was prepared from injecting a mixture of 50μg EAK and
19.5μg EAKH6 into a volume (1ml) of PBS. The mixture produced an insoluble structure
visually similar to EAK. On its own EAKH6 does not associate into aggregates as
evidenced by the lack of Congo red binding (figure 4-2 b). Mixture of EAK and EAKH6
also form a 3-dimensional gel-like substance, as evidenced in figure 4-2 d.
This result indicates that the spontaneous assembly of EAK is not disrupted by the
presence of EAKH6 at 4:1 (EAK: EAKH6) mole ratio. However, formation of insoluble
structure does not prove the existence of EAK-EAKH6 composite. The presence of the
Congo Red-stained structure could be caused by self-assembly of EAK with EAKH6
excluded and remained in the aqueous solution. Evidence will be presented in the
following chapters to support the notion that EAKH6 is indeed integrated into the EAK
network.
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Figure 4-2: Formation of the peptide assembly. (a) Fibrillar structure formed
from 50μg EAK was revealed by Congo red (1μg/ml) staining in 1ml PBS, but not
in 1ml ddH2O, (b) Congo red staining of β-sheet-rich structures in PBS containing
EAK, EAK-EAKH6 and EAKH6 by itself, and self-supporting structure of (c) EAK,
(d) EAK-EAKH6 gel-like structure in an inverted vial.
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Characterization of the fibrillar structure composition
The fraction of EAKH6 associated with EAK was determined indirectly based on
quantity of peptides remained in the aqueous phase after centrifugation. At 16,000×g
EAKH6 associated with the EAK fibrillar structure can be removed from the aqueous
phase. The concentration of EAKH6 remained in the aqueous phase was determined
using UV-Vis (absorbance by peptide bond at 205 nm) based on Beer‟s law (figure 4-3
a). The results are summarized in figure 4-3 b. The difference between the mixture of two
peptides and EAK alone is significantly lower than the equal amount of EAKH6 by itself.
The percentage of EAKH6 incorporated into the fibrillar structure was calculated
according to the equation 4-2.

Equation 4-2

Based on the results from three independent experiments, 54.9±5.6% of the EAKH6
was removed from the solution by centrifugation with the EAK assembly. The
assumption here is that 100% EAKH6 on its own remain soluble and stay in the
supernatant. These data indicate that more than half of the mixed EAKH6 can be
incorporated into the network. This indirect measurement supports the fibrillar structure
consists of both EAK and EAKH6.
UV-Vis absorbance assays are fast and convenient for determination of protein/peptide
concentration, and do not consume the samples. Proteins in solution absorb ultraviolet
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light with absorbance maxima at 280 and 190nm. Amino acids with aromatic rings,
tyrosine and tryptophan, are the primary reason for the absorbance peak at 280 nm.[90]
Since neither EAK nor EAKH6 contains these amino acid residues, the other strong
absorbance by peptide bonds peaked at about 190 nm was used. Because of the
difficulties caused by absorption by oxygen and the low output of conventional
spectrophotometers at this wavelength, measurements are more conveniently made at 205
nm, at which the absorbance is approximately half that at 190 nm. The advantage of
using peptide bond absorbance is that there is little variation in response between
different proteins/peptides.[91]
Based on the outcome of UV-Vis analysis, a major part of EAKH6 was centrifuged
away from the supernatant in the presence of EAK. Since EAKH6 is soluble by itself, it
must associate with the EAK structure and get precipitated out.
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Figure 4-3: UV-Vis analysis of peptide aggregates. (a) Schematic of sample
preparation, and (b) UV-Vis absorbance at 205 nm of the supernatants (n=3).
The value of AEAK+EAKH6-AEAK is significantly lower than the value of AEAKH6 by
one-tail t-test (p<0.01)
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Chemical evidence of EAKH6 integration into EAK
The presence of the H6 domain in the EAK-EAKH6 composite was confirmed using
FTIR spectroscopy (figure 4-4). The fibrillar structure was formed by injecting a mixture
of EAK and EAKH6 (mole ratio 2:1, dissolved in water) into 1ml PBS, followed by
centrifugation to remove unbound EAKH6. The aggregates collected were then
lyophilized and subjected to FTIR scanning. The FTIR spectra of EAK-EAKH6 assembly
and pure EAK were recorded and represented as percent transmittance as a function of
wave-numbers (figure 4-4 a). Contribution of EAKH6 in the composite was obtained by
subtracting the spectrum of EAK from that of EAK-EAKH6 (figure 4-4 c).
In figure 4-4 a, the spectrum of EAK-EAKH6 shows peaks in the 900-500 cm-1
region, while there is no such peaks in the spectrum of EAK. Aromatic and
heteroaromatic compounds display strong out-of-plane C-H bending and ring bending
absorption bands in this region.[92] The presence of EAKH6 in the EAK-EAKH6
assembly can be evidenced by these bands in the aromatic ring vibration region since
EAKH6 contains imidazole rings in its histidine side chains (figure 4-6b).
Figure 4-6 c shows the net contribution of EAKH6 in the mixed peptide assemblies.
The presence of histidine is evidenced by the characteristics bands consistent with the
chemical features of the imidazole ring (figure 4-6 c).[92-94] Among these are peaks
characteristics of stretching of the double bonds C4=C5 at 1529 cm-1. The peak at 3274
cm-1 is assigned to the stretching vibration of C-H (C5-H and C2-H) in the imidazole
ring.[94,

95]

A broad band centered at 1134 cm-1 is typical of the tautomeric forms of

imidazole in the stretching of C2-N3 and C4-N3. The peak at 1051cm-1 represents C-H
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bending at C4 and C5 of the imidazole ring. The peaks at 541 and 721 cm-1 are consistent
with deformation vibration of ring structures, again supporting the presence of imidazole.
Since the EAK sequence contains no ring structures, the composite must contain the H6
domain. These spectroscopic results thus confirmed the presence of EAKH6 in the
assemblies formed by a mixture of EAK and EAKH6.
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(a)

(b)

(c)

Figure 4-4: FTIR confirmation of EAKH6 in EAK-EAKH6 insoluble structure.
(a) Fourier Transform Infrared (FTIR) spectra of lyophilized pure EAK and EAKEAKH6 insoluble structure, (b) chemical structures of EAK and EAKH6, and (c)
Imidazole-specific peaks were assigned to spectra of EAK-EAKH6 subtracted
with EAK. Peptides (dissolved in deionized water) were pipetted into 1ml PBS
and collected by centrifugation (16,000×g for 20 min at 25°C). Samples were
washed with PBS to remove weakly bound peptides not integrated into the
assembly and subsequently lyophilized before scanning over 400-4000cm-1.
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Infrared spectrum is obtained when radiation in the range of 4000-400 cm-1 is absorbed
and converted by an organic molecule into energy of molecular vibration. There are two
main types of molecular vibrations: stretching and bending. The stretching frequencies
are usually higher than corresponding bending because it needs more energy to stretch a
bond than bend it. The two important areas for a preliminary examination of a spectrum
are the regions 4000-1300 and 900-500 cm-1. The high-frequency portion of the spectrum
is called the functional group region. This region tends to include motions, generally
stretching vibrations, that are more localized and characteristic of the typical functional
groups, e.g., O-H, C-H, N-H, found in organic molecules. Meanwhile the region of 900500 cm-1 involves usually molecular bending motions, which are characteristic for an
aromatic or heteroaromatic structure.[96] In the current system, the presence of imidazole
ring in the EAK-EAKH6 composite can be confirmed by the peaks at 541,721 and 989
cm-1.
The identification of a compound using IR spectroscopy relies heavily on the
characteristic functional group frequencies. Certain groups of atoms give rise to bands at
or near the same frequency regardless of the structure of the rest of the chemical
environment. Based on this theory, the expectation is that the spectral contributions
detected were only those of the poly-histidines by including the spectral signatures of the
EAK as a background to be subtracted from the EAK-EAKH6 composite. In comparing
to the spectrum of an authentic sample, most of the peaks in the subtraction spectrum
match the characteristic peaks of histidine (i.e., C-H stretching at 3274 cm-1, C=C
stretching at 1529 cm-1, C-N stretching at 1134 cm-1). The analysis is completed over
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1024 scans and results are presented as an average of all 1024 scans, which strengths the
case for sufficient background subtraction, and supports the strength of this evidence for
EAKH6 presence in the fibrillar structure.
The IR spectroscopic analysis of the assemblies (collected by centrifugation) indicates
that at least some of the added EAKH6 associated with the EAK assembly. One
possibility is that the EAKH6 intercalates into the β-sheet stacks of EAK, thus becoming
an integral part of the fibrillar structure. The other possibility is that EAK form the
structure by itself with EAKH6 adsorbed physically, perhaps on the surface of the
assembly. Neither UV-Vis analysis nor IR spectroscopy could offer mechanism of
EAKH6 association with EAK. Thus further investigations to reveal the conformational
change of EAKH6 when associate with EAK are warranted.
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EAK induces EAKH6 conformational change
For EAKH6 to integrate into the EAK β-sheets, the former must undergo a change in
conformation. Circular dichroism (CD) was used to determine the dominant secondary
structure of EAK, EAKH6 and EAKH6 in the presence of EAK (figure 4-5). The
spectrum for EAK (figure 4-5 a) shows a broad negative maximum at ~216nm and a
positive band near 200 nm, a profile consistent with a predominant β-sheet conformation.
In contrast, the spectra of EAKH6 (figure 4-5 a) exhibits double minima at 206 and
222nm, which are characteristic of α-helix conformation.[97] These spectra of individual
peptide formed the basis of analyzing EAKH6 in the presence of EAK.
Mixtures of EAKH6 and EAK at mole ratios of 1:2 and 1:4 were also analyzed.
Spectroscopic contribution by EAKH6 was determined by subtracting the contribution of
EAK based on the spectrum of the pure peptide. This analysis indicates that EAKH6
underwent conformational change from a predominant α-helix to contain β-strand
conformation in the presence of EAK (figure 4-5 b).
The relative proportions of secondary structure compositions of the peptides were
analyzed using the algorithms operated in the de-convolution program CD-Pro. The
percentage of four secondary structure components, helix, strands, turn and random coil,
were estimated by comparing with reference proteins from a database of 43 soluble
proteins.[98, 99] Figure 4-5 c shows the results of the analysis. EAK, as expected, adopts a
high percentage of β-strand conformation at 58%, with the rest in turn and random coil.
By itself EAKH6 exhibits a mixed secondary structures, containing 14~17% of β-strand
and 24~28% of helix conformation. In the presence of EAK, however, the β-strand
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fraction of EAKH6 increased to 86% at the mole ratio 1:2 (EAKH6: EAK), and 92% at
1:4. Taken together, these data indicate that EAK induces EAKH6 undergo αβ
conformational change at the microscopic level. It is consistent with the notion of
integration of EAKH6 into EAK insoluble structure that consists of oligomerization of βsheets.
The pathway of EAKH6 association with the EAK structure was explored based on
secondary structure composition. CD measures the differential absorption of the left and
right circularly polarized components of plane-polarized radiation. This effect will occur
when a chromophore is chiral, or optically active.[97] All 20 natural amino acids, except
glycine, possess a center of asymmetry at the α carbon atom. Hence different forms of
regular secondary structure found in peptides and proteins exhibit distinct far-UV CD
spectra at 180-250 nm, where the peptide bond is the chromophore. In solutions, EAK
and EAKH6 adopted distinctly different conformations.

The basic principle involved in

the analysis of CD spectra, and used in the estimation of secondary structure factions, is
that the CD spectrum (Cλ) can be expressed as a linear combination of CD spectra of
individual secondary structure components (k), Bkλ.

C fkBk Equation. 4-3
Where fk is the fraction of the secondary structure k. This equation has been validated by
Sreerama et al., in2000.[98] Spectra of model polypeptides or of a set of reference
proteins with known structures are used to determine the component secondary structure
spectra Bkλ. The secondary structure fractions for the reference proteins are determined
from the corresponding crystal structure. The criteria to choose a reference set is based on
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Figure 4-5: Conformational analysis of EAK and EAKH6. Spectra of EAK and
EAKH6 in solution by itself (a) and net contribution of EAKH6 in the presence of
EAK (b). Relative fractions of secondary structures in each were de-convoluted
using CDPro (c). Data shown represents two independent experiments
conducted.
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the wavelength range and the nature of the sample peptides, native or denatured.
Otherwise, a reference set with the largest number of proteins should normally be
chosen.[98,

99]

Therefore, the secondary structure fractions analysis used a 43 soluble

protein set, in which the work of Johnson et al., Keiderling et al., Yang et al., and
Sreerama et al., was combined. [100-103]
EAKH6 would most likely retain its helical conformation if it merely adsorbs onto the
EAK structure. The CD analysis, however, reveals that EAKH6 undergoes αβ
conformational change in the presence of EAK. The most likely cause for this change is
that EAKH6 is integrated into the β-sheet stacks of EAK, forming complementary
hydrophilic and hydrophobic interactions among glutamate/lysine and alanine,
respectively.
The results further suggest that the higher the mole ratio of EAK to EAKH6, the more
β-strand fraction in EAKH6. A possible explanation could be EAKH6 is much more
dispersed in the matrix of EAK at higher mole ratio, and is forced to line up with the βsheets by the surrounding EAK molecules. Based upon the β fraction of EAKH6 at
various mixing ratio (figure 4-5b), a mole ratio of 1:4 (EAKH6 to EAK) is sufficient to
obtain almost 100% of the added EAKH6 integrated into the β-sheets of EAK.
It is likely that only the amphiphilic domain (AEAEAKAK)2 of EAKH6 intercalated
into the β-sheets, with the non-complementary H6 domain extending from the EAKEAKH6 assembly. To prove this, an evaluation of the accessibility of H6 domain in
EAK-EAKH6 composite is required.
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EAK-EAKH6 composite displays H6 domains
A biochemical assay based on the enzymatic reaction of nickel conjugated horseradish
peroxidase (HRP-Ni) was performed to determine the accessibility of H6 domains in the
EAK-EAKH6 composite. HRP is an efficient enzyme which converts the substrate
3,3‟,5,5‟ tetramethylbenzidine (TMB) into two-electron oxidation product, diimine, with
the Km~3.6μM.[104] The reaction rate is coupled to colorimetric change.[104] Through
nickel coordination HRP-Ni can bind to the histidines specifically.[105] The assay was
performed by incubating HRP-Ni with the assemblies. EAKH6 integrated into the EAK
assembly should display the non-complementary H6 domains for binding with HRP-Ni.
Assembly associated HRP-Ni can be removed by centrifugation (16,000×g) and filtration
(0.22μm) from solution in which unbound HRP-Ni would remain. The amount of
unbound HRP-Ni remained in the solution was quantified by the catalysis of TMB
manifested in chromogenic change measured (λ=450nm). The amounts of free HRP-Ni
were then calculated according to a standard curve relating observed optical density to
known concentrations of HRP-Ni. The results are summarized in figure 4-6. The
concentration of HRP-Ni in EAK-EAKH6 group was found significantly lower than the
other groups by ANOVA and Tukey‟s multiple comparison tests, which suggested most
of the HRP-Ni bound to the composite.
Results are normalized to samples HRP-Ni processed without any peptides, which
represent the maximal possible amount of the enzyme remained in solution. Only
7.8±4.5% of the added HRP-Ni remained in the supernatant of EAK-EAKH6 composite.
89.5±13.3% and 83.1±15.0% of HRP-Ni were found unbound in the supernatant of pure
EAK and pure EAKH6, respectively. Therefore, it can be deduced that approximately at
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least 90% of the HRP-Ni bound to H6 domains in the assembly and was removed from
solution by centrifugation. Although EAK formed the assembly and was centrifuged and
filtered removed, HRP-Ni remained in the filtrate because it does not bind to EAK. It is
possible that HRP-Ni could bind to EAKH6, but these complexes are likely low
molecular weight species and therefore passed through the filtration step. Hence, the
disappearance of HRP-Ni from the supernatant of EAK-EAKH6 is caused neither by
non-specific adsorption to the assembly, nor by complexation with free EAKH6. Taken
together, these results add to the evidence of integration of EAKH6 into EAK and that the
composite display solvent accessible H6 domain. These H6 domains extruding from the
EAK-EAKH6 composite can be recognized by reactive agents, thus work as mounting
sites to modify the peptide assembly.
Additionally, these results were repeated for samples taken from the supernatant with
the EAK-EAKH6 formed and incubated at 37 °C, 5% CO2 for days, figure 4-6 c. The H6
domain was thus demonstrated to be stable in EAK-EAKH6 structure over one week.
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(c)

Figure 4-6: Probing H6 domains in EAK-EAKH6 composite. Peptide
structures formed in PBS were incubated with HRP-Ni for 60 min at 4°C.
Samples were then collected by centrifugation (16,000×g) and filtered (0.22μm)
to remove residual aggregates. The amount of HRP-Ni remained in the filtrates
(i.e. not bound to the structure) was quantified using a colorimetric method with
TMB as the substrate (with reaction terminated with H2SO4, λ=450nm). (a)
Concentrations of the enzyme were determined using a standard curve (range:
0.125 ng/ml to 8 ng/ml) reflecting a linear function: y=1.04x-0.15(r2=0.98).
Differences among EAK-EAKH6 and EAK, EAKH6 and PBS were statistically
significant (*p<0.001, n=3) based on ANOVA and Tukey’s Multiple Comparison
Test (α=0.05). (b) Color contrasts among and absence of aggregates in the
samples. Samples with HRP-Ni added to buffered saline without EAK or EAKH6
were included to reflect maximal enzyme recovery. (c) shows the stability of H6
function in the composite kept in PBS at 37°C and 5% CO2 over seven days.
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SUMMARY AND CONCLUSIONS
To transform the EAK β-sheet network into a structure for antibody immobilization a
versatile mounting mechanism is needed. To this end, a modified EAK peptide with six
histidines (H6) appended at the C-terminal was used to introduce mounting sites. H6
domains can be recognized by anti-poly-histidine (anti-H6) antibodies and interact with
metals such as nickel and cobalt through coordination bonds. The modified peptide,
referred hereafter as “EAKH6”, was designed on the basis that the amphiphilic domain
[AEAEAKAK]2 intercalates into the crossed β-sheets of EAK to form a composite in
which the H6 domains freely accessible. The assumption is that the histidine appendage
does not interfere with the ability of the amphiphilic domain to engage the same in EAK
oligomers. The integration of EAKH6 in the EAK structures was examined using UV-Vis
FTIR, CD and a biochemical assay (HRP-Ni). FTIR spectra clearly show the presence of
imidazole ring in the EAK-EAKH6 composite. In the presence of EAK, EAKH6
undergoes a distinct conformational change, from α-helix to β-strand. A biochemical
assay based on the enzymatic reaction of HRP-Ni was performed to determine the
accessibility of H6 domains in the EAK-EAKH6 composite. Results from this study
show that the EAK-EAKH6 composite can capture up to 90% of the metal-enzyme
conjugate, thus proving the functional property of H6 domains. Collective interpretation
of the results in the aforementioned studies confirms the integration of EAKH6 into EAK
assembly and that the associated H6 domains are accessible.
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CHAPTER 5
FUNCTIONALIZATION OF EAK-EAKH6 COMPOSITE WITH PROTEIN A/G
AS THE ADAPTOR
INTRODUCTION
Results described in the previous chapter demonstrate that H6 domain can be
introduced into the peptide assembly by the integration of EAKH6. H6 associated with
the assembly can be recognized by anti-H6 antibodies and interact with the divalent metal
nickel. In the current chapter, results will be shown to demonstrate the functionalization
of the EAK-EAKH6 assembly via the H6 domain. Specifically, IgG molecules will be
mounted onto the insoluble structure such that the (capture) antibodies are displayed and
clustered. To this end, a linker is needed to connect the capture antibody and H6 domains
of the assembly. Protein A/G, which contains six Fc-binding sites for immunoglobulins,
will be used to form the construct on which IgG molecules can be concentrated for the
purpose of binding cells or soluble molecules.
Protein A/G is a recombinant fusion protein with six Fc-binding domains combined:
four from protein A and two from protein G.[106] Protein A is a cell wall component
produced by several strains of Staphylococcus aureus. It consists of a single polypeptide
chain with M.W 42,000Da with four high-affinity (Ka=108/mole) binding sites capable of
interacting with the Fc region of IgG structures. Maximal interaction occurs at pH8.2,
although good binding takes place at neutral or physiological conditions (pH 7.0-7.6)
(figure 5-1 a).[107, 108] Protein G is also a bacterial cell wall protein isolated from group G
Streptococci. Native protein G contains two Fc-binding sites, as well as albumin and cell
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surface interacting domains. In the recombinant form, the albumin and cell surface
binding domains are eliminated to reduce nonspecific interactions. It has been reported
that most mammalian immunoglobulins bind with greater affinity to protein G than
protein A. Maximal binding occurs at pH 5, although good interaction is observed at pH
7.0-7.2.[109-111] Recombinant DNA of Fc-binding domains of protein A and protein G
results in a chimeric protein with broader binding activity than either protein A or protein
G alone. Recombinant protein A/G (hereafter referred to as rpAG) thus binds to all
human and mouse IgG subclasses. Binding of rpAG is also less pH-dependent, with good
interaction in the pH range between 5 and 8 (figure 5-1 a). [106]
By taking advantage of the Fc-binding capability of rpAG, a bi-functional complex
was designed by coating rpAG with both the capture antibody and an anti-H6 antibody.
The EAK-EAKH6 assembly is thus functionalized via its H6 domains through anti-H6
antibodies (figure 5-1 c). IgG is a “Y”-shaped macromolecule, with typical molecular
weight greater than 150KDa. The structure consists of three distinct domains. Limited
digestion with the protease papain cleaves antibody molecules into three fragments,
yielding two identical fragments termed the Fab (i.e. fragment antigen binding) and the
Fc fragment. The Fc domain plays an important role in the functions of antibodies by
activating the complement pathway, or recruit cytolytic effects of phagocytes and natural
killer cells via Fc receptors.[4, 112] Such structural configuration and functional segregation
allows one to use Fc as an anchoring site to display Fab for binding antigens, as
demonstrated in the studies to be described in the following chapter.
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Figure 5-1: Protein A/G and antibody. (a) Comparison of the binding
characteristics of mouse IgG at various buffer pH levels. Reprinted by
permission from International Scientific Communications (ISC): [American
Biotechnology Laboratory] (Vol.7 Page 42), 1989. (b) Schematic of using protein
A/G as the adaptor to mount the capture antibody to EAK-EAKH6. (c) Structure
of an IgG and its fragments. Reprinted with permission from © 2005 Grand
Sciences Publishing: [Immunobiology] (6th edition, Page17).
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MATERIALS AND METHODS
Protein A/G and antibodies
rpAG was obtained from Pierce (Rockford, IL, USA). This protein was expressed in
Bacillus and secreted into the surrounding medium during fermentation. It was supplied
as salt-free lyophilized powder. Upon receiving, it was reconstituted into a stock
concentration of 2.5mg/ml in sterile deionized water, and stored as aliquots of 50μl in the
freezer (-80°C) until use. The strong binding affinity of rpAG to mouse and rabbit IgG
subclasses has been proved. Rabbit anti-H6 polyclonal antibody was obtained from
AnaSpec, Inc (San Jose, CA, USA). This antibody was affinity purified and supplied as
0.2mg/ml solution in PBS (pH 7.4) with 0.2% bovine serum albumin (BSA) and 0.05%
sodium azide. It was stored in the refrigerator (4 °C) until use. Fluorescein isothiocyanate
(FITC) conjugated anti-mouse CD8a antibody was obtained from BD Biosciences (San
Jose, CA, USA). This fluorescent antibody was provided as 0.5mg/ml in aqueous
buffered solution containing ≤0.09% sodium azide. Up on arrival it was stored in the
refrigerator (4 °C) and protected from exposure to light。
Loading antibodies onto EAK-EAKH6 assembly
The complexes of rpAG and antibodies were prepared by incubating the antibodies
with rpAG. 0.1μg rpAG was coated with 1μg anti-H6 antibody first (molar ratio 1:3). The
capture antibody, anti-CD8a antibody, 1μg (mole ratio of rpAG to anti-CD8a 1:3) was
then added to make the complexes. Thus the six Fc binding sites of a rpAG were
saturated, and each molecule of rpAG carried both anti-His6 and anti-CD8a antibodies. A
FITC conjugated anti-CD8a antibody was used for the purpose of confocal analysis. The
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complexes were then mixed with peptides solution, and the mixture solution was injected
into 1ml PBS containing 10% fetal bovine serum (FBS) to initiate the insoluble structure
forming. FBS was added here to minimize the nonspecific binding. Aggregates were
mounted onto slides for confocal analysis.
Preparation of primary murine splenocytes suspension
Six to eight weeks old female (certified virus free) C57BL/6 mice were purchased
from Charles River Laboratories International Inc. (Wilmington, MA, USA) and housed
in the Duquesne University Animal Care Facility. All experimentation was handled in
accordance with institutional animal care policy. To obtain primary murine splenocytes,
the spleen was removed from the mouse, and grinded in 5 ml Rosewell Park Memorial
Institute (RPMI) medium (HyClone Laboratories, Inc. Logan, UT, USA) containing 10%
heat-inactivated fetal bovine serum (FBS) (HyClone), 50 μM 2-mercaptoethanol (Acros
Organics, Geel, Belgium), 1% antibiotics (penicillin/streptomycin) (Lonza Walkersville,
Inc. Walkersville, MD, USA). The cells were then spun down and resuspended in ACK
lysis buffer followed by incubation in ice for 5 min to remove red blood cells. After that,
the splenocytes were purified by passing through a nylon mesh (70 micron pore size),
washed and suspended in PBS containing 10% FBS to the final concentration of 1×106
cells /ml.
Apply splenocytes to antibody mounted EAK-EAKH6 assembly
The anti-CD4 antibody mounted EAK-EAKH6 assemblies were formed as described
above in 6-well plate containing 2 ml complete RPMI (10% FBS and 1% antibiotics
included) in each well. Assembly formed with EAK alone with everything else was
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included as a control. 2ml murine splenocytes suspension (1×106 cells/ml) in complete
RPMI medium was applied to each well to achieve a final concentration of 0.5×106
cells/ml. The plate was then incubated at 37°C for 24 hours. The peptide assemblies
were then imaged for investigation of their integrity.
Microscopic imaging
Peptide assemblies with cell captured were mounted onto microscope slides with
ProLong Gold antifade reagent (Invitrogen, OR, USA). A Zeiss AxioObserver Z1
inverted microscope (Carl Zeiss MicroImaging GmbH, Germany) was used to collect
imaging data. The microscope is equipped with digital image correlation (DIC) capability
illuminated by 100w bright-field and 300w liquid light-guide channeled Xenon light
sources for white light and fluorescence wide-field observation. The bright-field images
and fluorescent images are captured by QImaging MicroPublisher 22159 digital CCD
color microscope camera and high-sensitivity Hamamatsu C9100-02 electron multiplier
CCD camera, respectively. The images were analyzed using a SimplePCI imaging
software program (Hamamatsu Corporation, Sewickley, PA, USA).
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RESULTS AND DISCUSSION
The objective of this study was to determine the ability of EAK-EAKH6 assembly to
display a specific antibody via rpAG as the adapter, building upon the work described in
chapter 4, which shows the presence and accessibility of H6 domains in the EAKEAKH6 assembly. In this study, a fluorescent conjugated antibody was used for detecting
its association with the peptide assembly.
Immobilization of FITC conjugated antibodies on EAK-EAKH6 assembly
Capture antibodies were immobilized on EAK-EAKH6 assembly by using rpAG as the
adapter. rpAG (22 pmol) was coated with anti-H6 (67 pmol) and the capture antibody (67
pmol), resulting in mole ratio of 1:3:3 (rpAG to antibodies) (table 5-1). Thus, all six Fc
binding sites on rpAG should be saturated. The now bi-specific rpAG was then mixed
with EAK and EAKH6 (dissolved in water), and injected into a volume of PBS
containing 10% serum. The ability of the adaptor to concentrate antibodies on EAKEAKH6 was first tested using rpAG equilibrated with an anti-H6 antibody and a
fluorescent (FITC)-conjugated anti-CD8a IgG.
rpAG complexed with the antibodies mixed with EAK-EAKH6 showed concentrated
fluorescence (figure 5-2), while only a low level of fluorescence was observed when the
antibody was complexed with the EAK assembly. These results indicate for the
immobilization of the anti-CD8a antibody on the EAK-EAKH6 assembly. The assembly
prepared with EAK only did not concentrate the antibody, suggesting a lack of interaction
between the rpAG complex with the structure. When kept in serum containing PBS at
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4°C for one week, the EAK-EAKH6/antibody construct remained intact, as evidenced by
the fluorescence observed on day 7 of incubation (figure 5-2).
These data are consistent with the interpretation of the analytical results described in
Chapter 4. In particular, the presence of functional H6 domains in the EAK-EAKH6
assembly is reinforced. In addition, the current data confirm the feasibility of the design
of using anti-H6 antibody coated rpAG to mount capture antibodies onto the assembly.
Furthermore, in the presence of serum proteins, which saturated the non-specific binding
sites, the complex did not bind to EAK assembly. One can therefore assume that the H6
domains are indispensable for loading the FITC-conjugated antibodies.
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M.W

Stock Conc.

rpAG

50kDa

0.25μg/μl

Total mass used
for the construct
1.1μg

Moles used for the
construct
-11
2.2×10

Anti-H6
antibody
FITC-antiCD8a antibody
EAKH6

150kDa

0.2 μg/μl

10μg

6.7×10

150kDa

0.5 μg/μl

10μg

6.7×10

2479.7

7.8 μg/μl

78μg

3145.5×10

EAK

1656.2

5μg/μl

200μg

12075.8×10

Mole Ratio
1

-11

3

-11

3

-11

-11

1430
5489

Table 5-1: Stoichiometry of rpAG, antibodies and peptides. Peptides
assembly was formed by EAK and EAKH6 at mole ratio of (4:1). The six Fc
binding sites of rpAG were saturated by anti-H6 and anti-CD8a antibodies, both
at the mole ratio of 1:3 (rpAG to antibody). The mole ratio of EAKH6 to anti-His6
antibody is about 500:1 to ensure there are plenty of H6 domains to bind with.
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Figure 5-2: Displaying IgG molecules on (a) EAK and (b) EAK-EAKH6. (a1),
(b1) incubated in serum containing PBS for 24 hours; (a2), (b2) incubated for
5days; (a3), (b3) incubated for 7days. Peptide structures were mounted with
rpAG equilibrated with rabbit anti-H6 Ab and a fluorescein-conjugated IgG with a
molar ratio of 1:3:3 such that all six Fc binding sites on protein A/G are occupied
by either antibody. Bovine sera (10% v/v) were included to minimize non-specific
binding. The peptide structures were transferred to glass slides and analyzed
using a Zeiss AxioObserver microscope (operating the SimplePCI imaging
software). Images shown are representative of two independent experiments
conducted.
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As stated above, each rpAG molecule has six Fc-binding sites for antibody. In order to
use rpAG as the adaptor to bridge the capture antibody to the EAK-EAKH6 assembly,
every rpAG molecule carrying the capture antibody must have at least one anti-H6
antibody attached as well. To achieve this goal, rpAG was coated with anti-H6 antibodies
at the mole ratio of 1:3 as the first step in the process of making the constructs. By this
way, half of the antibody-binding sites in rpAG molecules were occupied and the other
half remained available for the capture antibody. The assumption is that anti-H6 antibody
molecules added are evenly equilibrated with rpAG. This strategy was validated by the
results showed in figure 5-2.
The results in figure 5-2 support the use of rpAG-antibody complex to mount capture
antibody onto EAK-EAKH6 assembly. However, it is possible that the capture antibodies
lose their biological activities during the process. They could form aggregates, be
denatured, or the antigen-binding sites be covered by other components of the assembly.
Thus it is important to test the bio-function of the antibodies after they are mounted onto
EAK-EAKH6 assembly. Further studies will be conducted to test the ability of peptideantibody construct to capture cells.
Cellular compatibility of EAK-EAKH6 assembly
Materials developed as injectables or implants must be compatible with cells. As a
preliminary study, the integrity of the EAK-EAKH6 structure was examined when cocultured with leukocytes. Primary murine splenocytes suspended in complete RPMI
medium were applied to mouse IgG mounted EAK-EAKH6 assembly. The samples were
incubated at 37°C for 24 hours.
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The peptide assemblies were examined before and after incubated with cells, as shown
in figure 5-3. A group of peptide-IgG constructs formed in medium without any cells
was included as a control. As the images showed, overall integrity of the peptide
assembly remained largely the same after 24 hours culture with mouse spleen cells. The
accumulation of cells metabolites did not impact the β-sheet structures. No apparent
effects were seen from accumulation of carbonic and lactic acids released from metabolic
active cells. Components in animal (bovine) serum, including peptidases and proteases
appeared inert against the structure. Thus the results suggest that EAK-EAKH6
composite can reasonably sustain typical environment of living systems. It should be
noted that the issue of biological compatibility require long-term in vivo studies beyond
the scope of this work.
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Figure 5-3: Cell compatibility of EAK-EAKH6 IgG construct. (a) Images of
peptide assemblies in the cell culture wells. Primary mouse splenocytes were
applied with complete RPMI medium containing 10% FBS and 1% antibiotics. (b)
Zoomed in (digitally magnified) images.
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Concentration of IgG in vivo via EAK-EAKH6
The ability of the construct to assemble in vivo was examined in a preliminary study. A
solution of EAK and EAKH6 dissolved in deionized water mixed with rpAG equilibrated
with an anti-H6 antibody and IgG (conjugated with the PE dye) was injected
subcutaneously next to B16 tumors established in living animals (figure 5-4 a). Mice
received the injection were allowed to move freely in their cage and euthanized on the
next day, with the tumors and the adjacent tissues excised for analysis. The subcutaneous
small tumor was used as a reference point for ex vivo identification of the injection site.
All mice injected with the complex were found to behave normally, with no unusual
eating, drinking or grooming activities observed. Care was taken to preserve the tissue
integrity when tumors were excised. The insoluble EAK-EAKH6 structure could be
observed with Congo red staining (figure 5-4 b). Figure 5-4 c and d represent bright-field
image and xenon wide-field image of a same region of the recovered peptide assembly,
respectively. Observed was an area with significant red fluorescence, which could only
come from the PE-conjugated IgG molecules, injected with the EAK-EAKH6 assembly.
The locale of the fluorescence is in the same vicinity of the injection site. In contrast,
when IgG-PE was injected without the peptide assembly at a tumor established on the
opposite flank in the same mouse, no fluorescence could be detected (Figure 5-5). These
results indicate that free IgG administered in vivo failed to remain at the site of injection
but congregated when injected with EAK-EAKH6 and rpAG (anti-H6). Based on these
data, it can be concluded that EAK-EAKH6 serves to form His-tag displaying assemblies
in vivo. Concentration of antibody sustains for at least 24 h in vivo in the subcutaneous
space.
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Figure 5-4: Self-assembly of EAK-EAKH6 in vivo. (a) A solution containing
EAK, EAKH6, rpAG equilibrated with anti-H6 antibody and a IgG conjugated with
the red fluorescent dye (PE) was injected subcutaneously adjacent to a B16
tumor (~3 mm in diameter) established in a C57BL6 mouse. (b) After 24 h, the
area (the tumor and surrounding tissues) was excised and imaged. (c) Brightfield image showing the outline of the membrane; (d) Xenon wide-field image
showing the red fluorescence concentration in the membrane.
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Figure 5-5: Fluorescence conjugated anti-mouse IgG concentrated with
peptide assembly in vivo. (a), (b) PE-IgG complexed with rpAG and anti-H6
was injected with EAK-EAKH6 composite. (c), (d) same amount of PE-IgG was
injected by itself. (a) and (c) are bright-field images of the injection sites next to
the tumors. (b) and (d) are xenon sourced wide-field images of the fluoresce. .
No fluorescence was detectable when IgG-PE was injected by itself at a tumor
established on the opposite flank in the same mouse.
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Immunohistochemical analysis of self-assembling peptides injected in vivo did not
show overt inflammation.[68] Although these results suggest that self-assembling peptides
are non-immunogenic, studies testing long-term immunogenicity in vivo have still to be
performed. rpAG and the antibodies could dissociate and phagocytosed by APCs, but the
high-affinity interactions render this unlikely. The generation of neutralizing antibodies
against rpAG and/or the antibodies could occur in 10-14 days after digestion by APCs,
but in the absence of adjuvant, these entities should elicit only weak and short-lived IgG
or IgM responses. The use of humanized antibodies should reduce the overall
immunogenicity of the constructs. Protein A has also been used in immunoadsorption
treatments

(apheresis)

for

rheumatoid

arthritis

and

dilated

cardiomyopathy

(ClinicalTrials.gov Identifier NCT00558584). The incidence of adverse events, mainly
vasculitis, is low. [113] A Phase I clinical study of administering staphylococcal protein A
(PRTX-100) directly into healthy volunteers has been completed (ClinicalTrials.gov
Identifier NCT00517855). The lack of safety concerns drove the initiation of an ongoing
trial studying the effects of multiple doses of staphylococcal protein A in adult patients
with idiopathic thrombocytopenia purpura (ITP) in Australia (ClinicalTrials.gov
Identifier NCT00571467). These examples of clinical usage suggest an acceptable level
of biocompatibility of rpAG.
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SUMMARY AND CONCLUSIONS
The studies described in this chapter have implications for the applicability of the
system. The data show that IgG molecules can be concentrated via rpAG-antibody
complex directed toward H6 domains. This observation opens the possibility of a system
that can interact with cells and soluble molecules in a specific manner. Building upon the
data showing spontaneous integration and assembly of EAKH6 into EAK, the in vivo
experiments demonstrates a similar process can take place in the subcutaneous space.
The system proves to be amenable as an injectable material. A solution of EAK, EAKH6,
rpAG, anti-H6 antibody and IgG-PE injected subcutaneously assembled to concentrate
the fluorescent antibody at the injection site for at least 24 h. Presumably, the triggering
stimulus is the salt in the physiological environment. This stimuli-responsive nature of
EAK-EAKH6 is particularly useful. Because the crossed β-sheets insoluble structure
forms only in the presence of metal ions, the components of the construct can be kept as a
soluble system, allowing injecting through regular syringes, without the need for surgical
placement often required in the use of implanted drug delivery devices. Importantly,
complexation of rpAG with the antibodies remained intact during the injection, sustaining
the shear stress applied through the needle (255/8G). Taken together, the data support the
notion that EAK-EAKH6 can be used as a platform for displaying antibodies in vivo.
Ultimately, I envision the design may change how therapeutic antibodies are used and
delivered in man.
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CHAPTER 6
CAPTURE OF LEUKOCYTE SUBSETS IN FUNCTIONALIZED EAK-EAKH6
COMPOSITE
INTRODUCTION
Recent evidence has demonstrated that Treg cell-mediated immunosuppression is one
of the crucial mechanisms of unsuccessful tumor immunotherapy. Approaches to
physically deplete or functionally inactivate Treg cells have been developed to reverse
the tumor induced Treg cell expansion.[40, 42] Anti-Treg mAb can be used to deplete the
cells through antibody-dependent cellular cytotoxicity (ADCC) or block signaling
through surface receptors. The depleting anti-CD4 and CD25 have been tested in mice
with some success, and the signal modulators anti-CTLA4[7] and anti-GITR[54] have
shown promise. Several of these, including daclizumab (anti-CD25), and ipilimumab
(anti-CTLA4) are being tested in humans. A common feature from the results of the
clinical trials is autoimmune syndrome such as thyroditis (daclizumab) and colitis
(CTLA-4).[40, 42] Thus a more specific therapeutic strategy is required to prevent highdose and sustained therapy in refractory diseases. Another possible reason for the poor
clinical efficacy is that although the level of Treg cells is increased in tumor
microenviornment, the number of lymphocytes is still not comparable to tumor cells. The
tumor infiltrated lymphocytes were found to be <0.5% of the entire tumor cellularity. [41]
Given these, it is envisioned that a localized delivery system that enhance the functions of
the aforementioned anti-Treg antibodies could be decisive as adjuvant in tumor
immunotherapy. The EAK-EAKH6 structure characterized could be a potential carrier of
the antibodies. The objective of the research in this chapter was to determine the ability
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of EAK-EAKH6 assembly to trap T cells specifically in vitro via mounted surface
molecule specific antibodies. Achieving this milestone will provide an initial assessment
of EAK-EAKH6-antibody construct as a viable platform for engaging specific subset of
T cells in vivo. The rationale is that the selective and multiple binding between the
surface molecules and the antibodies displayed by EAK-EAKH6 should render a
particular type of T cells immobilized onto the peptide assembly. Anti-CD4 antibody was
used in the experiments to trap Treg cells. The level of Foxp3 expression was monitored
in the lymphocyte population since Foxp3 is the most distinctive marker for the
regulatory lineage.[114]
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MATERIALS AND METHODS
Apply murine splenocytes to constructed anti-CD4 antibody mounted EAK-EAKH6
composite
The purified unlabeled rat anti-mouse CD4 antibody, 0.5mg in 1.0ml of 100mM borate
buffered saline (pH 8.2), was purchased from SouthernBiotech (AL, USA). rpAG was
complexed with rabbit anti-H6 antibody and rat anti-mouse CD4 antibody at the mole
ratio 1:3:3 as described in chapter 5. The rpAG-antibody complexes and EAK, EKAH6
in water were then injected into 600μl serum containing PBS holded in BD Falcon TM cell
culture inserts (BD Biosciences, NJ, USA) with polyethylene terepthlate (PET)
membrane (8.0 μm pore size) accompanied by BD FalconTM cell culture insert
companion 24 well plate. The membrane insert made possible removal of residual
peptides and antibodies through repeated washing steps. Murine lymphocytes were
obtained from the spleen of a female C57BL/6 with late stage of melanoma, and made
into lymphocytes suspension, as described in chapter5, in PBS containing 10% FBS to a
concentration of 2×106 cells per ml. 2×106 cells were then applied to each well, and
gently shake for 1 hour at 4°C. The unbound cells were rinsed away by serum containing
PBS. This process was repeated for 4 times. The peptide assemblies with cell captured
were stained with FITC conjugated rat anti-mouse CD25 antibody (SouthernBiotech, AL,
USA), 2μg antibody per well, and mounted onto microscope slides for microscopy
analysis. Unbound cells were collected for semi-quantitative reverse transcription
polymerase chain reaction (RT-PCR). The procedure is illustrated in figure 6-1.
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Figure 6-1: Schematic of applying murine splenocytes to anti-CD4 antibody
mounted EAK-EAKH6 membrane. Lymphocytes were harvested from the
spleen of mice carrying B16 tumors. Single cell suspensions (2x106 cells/ml),
depleted of erythrocytes and monocytes, were placed onto aggregates of EAK
and EAK-EAKH6 established on mesh filters (pore size: 8 µm) for 4 h at 4°C.
This process was repeated four times. Samples on filters were transferred to
glass slides and analyzed under microscope. Unbound cells were collected for
PCR analysis.
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Microscopic imaging analysis
Peptide assemblies with cell captured were mounted onto microscope slides with
ProLong Gold antifade reagent (Invitrogen, OR, USA). A Zeiss AxioObserver Z1
inverted microscope (Carl Zeiss MicroImaging GmbH, Germany) was used to collect
imaging data. The microscope is equipped with digital image correlation (DIC) capability
illuminated by 100w bright-field and 300w liquid light-guide channeled Xenon light
sources for white light and fluorescence wide-field observation. The confocal capability
is provided by three acousto-optic tunable filter (AOTF) software-selectable
(488/568/647nm) Melles Griot Kr/Ar laser lines fed into a Yokagawa QLC 100 spinning
disc confocal head that is capable of analyzing 360 frames/sec. The bright-field images
and fluorescent images are captured by QImaging MicroPublisher 22159 digital CCD
color microscope camera and high-sensitivity Hamamatsu C9100-02 electron multiplier
CCD camera, respectively. The images were analyzed using a SimplePCI imaging
software program (Hamamatsu Corporation, Sewickley, PA, USA). The cells were
counted by the program of NIH ImageJ.
Semi-quantitative reverse transcription polymerase chain reaction (RT-PCR)
Total RNA of collected unbound cells was isolated using a SV total RNA isolation kit
(Promega, WI, USA). The qualities and concentrations of template RNA were
investigated by absorbance at 260nm and 280nm using a Beckman DU530 Life Science
UV/Vis Spectrometer (Beckman Coulter, Inc., CA, USA). Coupled RT-PCR was
performed using Masterscript Kit & Masterscript RT-PCR System (5 PRIME GmbH,
Hambrug, Germany) in an Eppendorf MasterCycler (Eppendorf, Hamburg, Germany). 2
μl of primer pairs (one reverse and one forward, 10μM each) specific for Foxp3 and β88

actin (R&D Systems, Minneapolis, MN) were added to 0.1-0.5 μg of RNA sample in a
reverse transcription (50 °C for 50 min) step, followed by denaturation (94 °C for 4 min).
The amplification steps consisted of 35 cycles of template denaturation (94 °C for 45 s),
primer annealing (55 °C for 45 s) and primer elongation (68 °C for 45 s). PCR products
were separated in 2% agarose gel, visualized by of ethidium bromide staining, and
analyzed using NIH ImageJ.
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RESULTS AND DISCUSSION
Evidence of CD25 positive T cells captured by anti-CD4 antibody mounted EAK-EAKH6
composite
The EAK-EAKH6 structure was loaded with an anti-CD4 antibody to test the capacity
of the design to capture CD4+ T cells. The construct was exposed to a mixed population
of mouse lymphocytes (including CD4, CD8 T cells, B cells and NK cells). These cells
were harvested from mice carrying B16 tumors, which have spleen populated with Treg
cells. Cell suspensions were applied onto the EAK-EAKH6 anti-CD4 construct formed
on polycarbonate mesh filters. Cells bound to the construct were stained with FITC
conjugated rat anti-mouse CD25 antibody and examined under microscope.
Bright-field images were captured on the same region at different magnifications. As
presented in figure 6-2, a greater extent of cell capture is evident in anti-CD4 antibody
mounted EAK-EAKH6 assembly (a1 through a4) compared to that in the EAK aggregate
(b1 through b4). Using ImageJ the cell density was estimated to be 200-1000 cells/mm2
in the EAK-EAKH6 construct, whereas only 10-40 cells/mm2 were captured by the EAK
structure. The micrographs show that cells are not adsorbed randomly at the surface, but
are ordered in heterogeneous clusters.
The captured cells in the EAK-EAKH6 structure were examined for their identities.
Figure 6-5 shows a representative for two independent experiments indicating that the
cells captured in the EAK-EAKH6 construct express CD25. Most likely, the cells are
Tregs. This result compliments the findings in the bright-field images to suggest that cells
were captured specifically through the antibodies displayed with minimal non-specific
cell adsorption to the EAK aggregate.
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Taken together, the data show that the design of EAK-EAKH6 and rpAG/anti-H6 can
be used to display mAb for purpose of capturing specific cell populations. The structure
formed by self-assembling structure with pores of about 5–200 nm have an extremely
high water content, >99.9–99.5% or 1–5 mg/ml (w/v).[57] These structures closely mimic
the porosity and structure of extra-cellular matrices, which allow tissue cells to reside and
migrate in a 3D environment. Hence these peptide scaffolds have been used for 3D cell
culture, controlled cell differentiation, tissue engineering, and regenerative medicine
applications. However, the non-specific adsorption of cells to the peptide assembly was
suggested not to be stress resistible. As figure 6-2 a1-a4 showed, most of the EAK
assembly adsorbed cells were washed away. In the meantime, the cells immobilized with
anti-CD4 antibodies stayed within the EAK-EAKH6 assembly after washing steps,
indicating a stable interaction with the peptide structure. This property is important for in
vivo application, especially in the tumor microenviorment that has higher perfusion rate
and interstitial pressure than normal tissues.

91

Figure 6-2: Capability of the anti-CD4 antibody mounted EAK-EAKH6
assembly to capture cells. Lymphocytes were harvested from the spleen of
mice carrying B16 tumors. Single cell suspensions (2×106 cells/ml), depleted of
erythrocytes and monocytes, were placed onto aggregates of (a) EAK, (b) EAKEAKH6 established on mesh filters for 4 h at 4 °C. This process was repeated
four times. Samples on filters were transferred to glass slides and analyzed at 5x
(a1), (b1); 10x (a2), (b2); 20x (a3), (b3); 40x magnification (a4), (b4). (c2), (c3),
(c4) cells associated with EAK-EAKH6 were enumerated using ImageJ. (d) Cell
count per area (mm2) at different magnifications was found related linearly (y=5.7x+321, R2=0.9789).
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Figure 6-3: Laser confocal images of CD25 staining. Cells bound to EAKEAKH6 (a) were stained with a fluorescein-conjugated Ab against CD25, a
surface molecule expressed by regulatory T cells. The same experiment was
performed with EAK aggregate (b) for comparison. (a1), (b1) bright-field images;
(a2), (b2) Kr/Ar laser sourced confocal images.
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Depletion of Foxp3 in unbound fraction
Unbound cells from figure 6-1 were collected and analyzed for Foxp3 expression level
by semi-quantitative PCR with specific primers. Foxp3 is a distinct intracellular marker
for Tregs.[115] Cells without passing through the anti-CD4 construct were used as the
control.
Figure 6-4 shows the Foxp3 expression in the respective cell fraction in agarose
electrophoretic migration. As expected, only products of Foxp3 (177 bp) and β-actin (154
bp) were detected. Band intensity was quantified to determine the relative amount of
transcripts in the cells. Unbound cells collected from the EAK assembly showed a high
level of Foxp3 expression, at approximately the same level with that of cells without
passing through any peptide construct. In contrast, Foxp3 expression was found
decreased by 90% in cells recovered from the EAK-EAKH6 construct. It can thus be
concluded that regulatory T cells can be depleted from the heterogeneous lymphocyte
suspension. These data are consistent with the microscopic images indicating that specific
cell subsets are captured onto the anti-CD4 EAK-EAKH6 construct. The ability of the
functionalized EAK-EAKH6 assembly to specifically capture cells via mounted mAb
was thereby confirmed in vitro.
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Figure 6-4: Evidence of EAK-EAKH6 used to deplete a specific T cell
population. The relative fractions of regulatory T cells remaining apart from
EAK-EAKH6 were quantified using semi-quantitative PCR based on expression
of Foxp3, a transcription factor that largely defines regulatory T cells. The cells
with no peptide-antibody construct incubation (referred to as blank) were used as
a control here to evaluate the effect of culture condition on the Foxp3 expression.
The band sizes were consistent with predicted PCR products of Foxp3 (177 bp)
and β-actin (154 bp). Data represent two independent experiments conducted.

95

It has been established that Foxp3 is a crucial factor for the functional development
of CD4+CD25+ regulatory T cells.[114] Initial support for the role of Foxp3 came from the
observation that high Foxp3 expression in peripheral and thymic CD25+ Treg cells in
mice. Conversely, Foxp3 could not be detected in CD25+ conventional activated T
cells.[114] The expression of Foxp3 in CD4+CD25+ thymocytes in wild-type mice and the
diminished numbers of CD4+CD25+ T cells in scurfy and Foxp3-knockout (Foxp3−)
mice implied a role for Foxp3 in Treg cell development. Ectopic expression of Foxp3 in
mouse CD4+CD25−Foxp3− T cells results in acquisition of suppressor properties. Foxp3
appears to exert parallel functions in mouse and humans. In humans, Foxp3 is also highly
expressed in CD4+CD25+ T cells with suppressor function and that Foxp3 gene transfer
confers suppressor functions to naive human CD4+ T cells.[33, 39, 114, 116] In light of these,
the evidence presented above suggests the construct has the potential to regulate the
abundance or accumulation of Treg cells in a defined microenvironment.
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SUMMARY AND CONCLUSIONS
In the previous chapter (5), evidence was presented to demonstrate that rpAG, anti-H6,
and EAK-EAKH6 could be combined to display mAb. The studies described in this
chapter serve to extend the feasibility of the construct by mixing with mouse
lymphocytes in vitro. The EAK-EAKH6 construct captured significant number of cells
(figure 6-2), and the lack of cells bound to the EAK construct suggest specific interaction
in the former. Two lines of evidence support specificity. Cells bound to the EAK-EAKH6
construct express CD25 (figure 6-3), and that unbound cells recovered had lower (90%
decreased) level of Foxp3 transcript than that of the same from the EAK assembly (figure
6-4). It can thus be concluded that the EAK structure first reported almost two decades
ago could be transformed from a non-specific matrix to a cell-selective structure in the
EAK-EAKH6 construct.
The EAK-EAKH6 composite coated with mAb can be loaded with bioactive
molecules, such as siRNA. Unlike the traditional concept of targeted drug delivery, in
which the therapeutic agent is required to travel through the systemic fluid to arrive at the
target cells, the current concept relies on co-localization of target cells with the
therapeutics. Characterization of this injectable system described herein is a step towards
applying the concept “reversed drug targeting” by which target cells are brought to a
reservoir of drug molecules. I have begun to explore this in two formats. First, the
membrane could be loaded with nucleic acids (used as a model drug) in the membrane.
Preliminary data (not shown) indicate a 90% loading efficiency of oligonucleotides in the
EAK-EAKH6 membrane, but only approximately 30% of that loaded was released after
seven days at 37˚C. A second option is to mount polymeric particles loaded with nucleic
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acids in or on the membrane. In this case the nucleic acids are released as a function of
particle degradation. Both scenarios are aimed to exploit the close proximity of target
cells and bioactive nucleic acids co-localized on a defined structure.
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CHAPTER 7
CHARACTERIZATION OF POL-(D, L-LACTIC-CO-GLYCOLIC ACID)
PARTICLES AS CARRIERS OF NUCLEIC ACIDS INTO PRIMARY
DENDRITIC CELLS AND T CELLS

INTRODUCTION
Dendritic cells (DCs) are pivotal in the regulation of immune responses.[117]
Modulation of DCs phenotypes with oligodeoxynucleotide (ODN) as decoys or antisense molecules can affect T-cell functions and immunity.[118, 119] Direct administration of
ODN in intact animals, however, results in unpredictable and often suboptimal effects.[120]
This can be attributed to inefficient accumulation of the ODN inside DCs due to
extracellular physicochemical (e.g., anionic charges of DNA) and enzymatic (e.g.,
nucleases) barriers.
Nanoparticles have been used as carriers of ODN to overcome these barriers.[121, 122]
The biodegradable co-polymer poly(D,L-lactide-co-glycolide) (PLGA) is a suitable
building block for forming nucleic acids carriers.[123, 124] PLGA particulates are stable in
vivo[125] and can be effectively engulfed into APCs by endocytosis.[126, 127] Theoretically,
a large number of DNA molecules can be internalized with each particle entry. A key
remaining barrier, however, is that internalized DNA molecules are channeled to
lysosomes and degraded. In vitro, this may be overcome by delivering a large amount of
the DNA and hope that some would escape. This is an inefficient process and high local
DNA concentration may not be possible to attain in vivo.
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Another challenge is the poor efficiency of loading macromolecules in PLGA particles
because the DNA is often damaged during the encapsulation process. Several groups
have addressed this by incorporating cationic species into PLGA to increase entrapment
of the DNA. Capan et al. have detailed the physical characteristics of microparticles of
plasmid DNA formulated with PLGA and poly-L-lysine (PLL).[128,

129]

Ravi et al.

described the preparation and characteristics of cationic PLGA nanospheres with
PVA−chitosan to adsorb DNA intended for gene delivery applications.[130] Li et al. have
used calcium-phosphate to precipitate plasmid DNA to form PLGA microparticles.[131]
Stearylamine[132] and polyethylenimine (PEI)[133] have also been used to encapsulate
plasmid DNA into PLGA microparticles. Kasturi et al. have shown that plasmid DNA
adsorbed on PEI-surface conjugated PLGA microparticles leads to enhanced gene
delivery in macrophages.[134]
In the work presented in this chapter, O10H6, an ornithine–histidine cationic peptide,
was employed to fulfill the dual functions of improving loading and enhancing the escape
of DNA from lysosomes. It has been shown previously that O10H6 forms stable
condensates with nucleic acids on the surface of carboxylate polystyrene microspheres
and this self-assembled system can facilitate DNA uptake in DCs.[135, 136] The imidazole
in histidine facilitates endosomal escape by disrupting the osmotic balance of the
vesicles.[137,

138]

Herein the physical characteristics and cellular uptake of PLGA

nanoparticles loaded with ODN pre-condensed with O10H6 were examined. The results
show that PLGAO10H6 is an effectual nucleic acids carrier capable of delivering ODN into
primary DCs. Evidence is shown for the cellular internalization and escape of the ODN
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from the lysosomal pathway in DCs. These results raise the prospect of applying DNAloaded PLGAO10H6 in DC modulation.
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MATERIALS AND METHODS
Peptide and oligodeoxynucleotide
The peptide O10H6 (figure 7-1 a; 1982 Da) was custom synthesized by SigmaGenosys (Houston, TX, USA) custom synthesis service. Crude peptides were purified by
HPLC (>90%) and their identities were confirmed by liquid chromatography-mass
spectrometry. Upon arrival, the lyophilized peptides were reconstituted in sterile ddH2O
at a concentration of 200 μg/μl (100 mM) and stored in 50-μl aliquots at −80 °C until use.
ODN with a phosphorothioate-modified backbone containing the NF-κB binding sites
(sense strand: 5’-AGGGACTTTCCGCTGGGGACTTTCC-3’) were custom synthesized
by Alpha DNA (Montreal, Quebec, Canada). The DNA was labeled with fluorescein
isocyanate (FITC) at the 5’ end. PLGA (50:50; 16.5–22 kDa; I.V.= 0.66–0.80) was
obtained from Polysciences (Warrington, PA, USA). Polyvinyl alcohol (PVA) (Fig3.1 a)
with a molecular mass of 22 kDa and 88% hydrolyzed was purchased from SigmaAldrich (St. Louis, MO, USA).
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Figure 7-1: Materials and methods of particles preparation. (a) Chemical
structures of PLGA, O10H6 and PVA used in making the particles. (b) A
schematic diagram of the particle fabrication process. A double-emulsion solvent
evaporation method was used.
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Preparation of PLGAO10H6-ODN nanoparticles
PLGAO10H6-ODN particles were prepared using a double-emulsion (w/o/w) solvent
evaporation technique (figure 7-1 b).[139] 5μg O10H6 was added to 200 μl of an aqueous
solution containing 40 μg of the ODN and gently shaken for 0.5 h at room temperature.
This aqueous solution was incorporated into a methylene chloride (MeCl2) solution of
PLGA (3%, w/v) by sonication. A Fisher model 100 sonic microprobe was used to
introduce 24 W of energy (over 2 min) to form this water-in-oil emulsion. This primary
emulsion was added drop wise with energy input (24W, 4 min) into 20 ml of aqueous
solution of PVA (0.5%, w/v) to form a water-in-oil-in-water emulsion. The resulting
double emulsion was stirred for 4 h in chemical fume hood to allow the MeCl2 to
evaporate. Particles were recovered by ultracentrifugation and washed twice with ddH2O
to remove excess PVA and un-trapped DNA. The particles used in the experiments
described were freshly prepared prior to each analysis. We have, however, determined
that the particles can be freeze-dried, stored, and be reconstituted in distilled water.
Freeze-dried PLGAO10H6-ODN retains 90% of their physical characteristics (particle size
and zeta potential) upon reconstitution. Addition of sucrose (2%, w/v) improves the
recovery to close to 100%. Loading efficiency was determined by dissolving the particles
in chloroform (2 h constant shaking) followed by extraction with Tris-EDTA buffers. The
aqueous phase was analyzed for DNA content with OligoGreen (Invitrogen/Molecular
Probes, Eugene, OR, USA; detection limit 100 pg/ml) to determine the amount entrapped
in the particles.[140] Loading efficiency was calculated based on the amount of ODN
determined divided by the amount of ODN initially added in the primary emulsion.
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Particle size and zeta potential analysis
The Nicomp 380 ZLS analyzer (Particle Sizing Systems, Santa Barbara, CA, USA)
was used to determine particle size distribution and zeta potential. Mean hydrodynamic
diameter was measured with particles suspended in ddH2O. The radius was calculated
using the Stokes–Einstein equation based on diffusion coefficient of the particles in the
medium. Data were integrated over 10 min in duplicate experiments and were test fit for
Gaussian and non-Gaussian functions. The instrument operates based on the dynamic
light scattering principle, capable of detecting particle size ranging from 5 nm to 5 μm.
Zeta potential measurement was performed with the samples diluted with ddH2O (pH
approximately 7.2) The measurement is based on electrophoretic mobility of the sample
particles when subjected to an electric field.
Transmission electron microscopy and infrared measurement
Transmission electron micrographs were obtained using a JEM-100 CXII electron
microscope (Jeol, Tokyo, Japan). A cool beam electron gun (60 kV) was used to
illuminate the samples. A PLGAO10H6-ODN suspension was dried on a copper grid
support (G200-CU; Electron Microscopy Sciences, Hartfield, PA, USA) and stained with
1% uranyl acetate for image capture. Images were captured from films developed using
high contrast D-19 developer (Kodak, Rochester, NY, USA). Reflectance FTIR spectra
were recorded on a Thermo Nexus 470 Infrared Spectrometer operated at a spectral
resolution of 0.5 cm−1 with 1024 scans. Particles were dried overnight in desiccators.
Samples were analyzed under inert conditions are scanned over the range of 400–4000
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cm−1. Independent measurements of PLGA, O10H6 and plastic support were obtained for
subtraction.
Mice and generation of primary DCs
Female certified virus free BALB/c (H-2d) mice (6–8 weeks old) were purchased from
Hilltop Lab Animals (Scottsdale, PA, USA) and housed in the Duquesne University
Animal Care Facility. All experimentations were handled in accordance with institutional
animal care policy. Primary DCs were generated from mice using the Inaba protocol [141]
with minor modifications.[142, 143] Total bone marrow cells were harvested from femurs
and cultured overnight in serum-free RPMI medium (Life Technologies, Gaithersburg,
MD, USA). Non-adherent cells were then re-plated at 106 cells/ml in 24-well tissueculture plates (Costar, Cambridge, MA, USA) in RPMI containing 10% heat-inactivated
FBS, 50 μM 2-mercaptoethanol, antibiotics (penicillin/streptomycin/fungizone) (all from
Life Technologies) and cytokines (5 ng/ml of murine GM-CSF and 5 ng/ml of murine
interleukin-4; R and D Systems, Minneapolis, MN, USA) and maintained at 37°C in 5%
CO2. On day 4, non-adherent cells were removed by aspirating 80–90% of the media and
adherent cells were re-fed with culture medium (1 ml/106 cells) containing GM-CSF and
IL-4.
For flow cytometric analysis, cultured DCs on day 6 of differentiation were exposed to
FITC-labeled free ODN (0.5 μM) or ODN encapsulated in PLGA or PLGAO10H6
(estimated ODN concentration = 100 nM) in 2 ml of Opti-MEM media for 2 h at 37°C
and 5% CO2. Particle density in the experiment was estimated to be 2.2×107 particles/ml,
based on the number of particles per unit area enumerated in TEM micrographs. After
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incubation, cells were then washed with PBS and analyzed using a Beckman Coulter
EPICS XL bench-top flow cytometer. At least 104 events were sampled for each group.
Confocal imaging
Cultured DCs were adhered to coverglasses, washed with PBS and incubated with
PLGAO10H6-ODN for 2 h at 37°C. Dendritic cells have an intrinsic propensity to adhere to
glass or plastic surface. A Fisher brand coverglass (22 × 22 mm) was placed in each well
in the bone marrow cultures. On day 6, the coverglass was recovered and adhered cells
were washed with PBS and fixed in 4% paraformaldehyde for 15 min at 4°C before
mounting on slides with an anti-fade medium (MOWIOL 4-88, CalBiochem, Darmstadt,
Germany). Images were collected using a Leica TCS SP-2 spectral microscope (Leica
Microsystems, Wetzlar, Germany) with an argon/helium laser and FITC filter.
Internalized DNA was visualized by fluorescence detection based on FITC-labeled ODN.
Lysosomes were illuminated by staining the cells with LysoTracker Red DND-99
(Invitrogen/Molecular

Probes),

a

red-fluorescent

dye

that

illuminates

acidic

compartments in live cells.
Foxp3 specific siRNA and preparation of siRNA adsorbed PLGA naoparticles
Double-stranded murine Foxp3-targeted siRNA (21bp) was designed and synthesized
by Ambion (Austin, TX, USA) (Figure 7-2). Upon arrival, the lyophilized siRNA were
reconstituted in sterile ddH2O at a concentration of 0.5μg/μl (100 mM) and stored in 50μl aliquots at −80 °C until use. In the uptake study, the siRNA was labeled with
carboxyfluorescein (FAM) at one of the 5’-ends.
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Figure 7-2: Sequence of Foxp3-targeted siRNA.

108

Plain PLGA particles were prepared in our lab using a double emulsion (w/o/w)
solvent evaporation technique described above. Particles were recovered by
ultracentrifugation and washed twice with ddH2O before lyophilization to remove excess
PVA and PLGA fragments. 60 mg of lyophilized PLGA was first coated with 200 mg of
O10H6 in 300 μL of ddH2O. To assure sufficient binding of O10H6 to the particles, the
components were equilibrated in a 1.5 mL Eppendorf tube with gentle shaking for 2
hours at room temperature on a mini shaker at a setting that is equivalent to the second
lowest speed. The resulting positively charged particles (denoted as PLGAO10H6) were
then equilibrated with the siRNA for an additional 30 min with gentle shaking at room
temperature. The N: P ratio for O10H6 to siRNA was estimated to be 10:1. The final
particle had siRNA condensed by O10H6 associated with the PLGA particle surface and
was referred to as PLGAO10H6-siRNA.
Physiochemical characterization of PLGAO10H6-siRNA
A Nicomp 380 ZLS analyzer (Particle Sizing Systems, Santa Barbara) was used to
determine the size and zeta potential of plain PLGA particles and PLGAO10H6-siRNA
particles.
In order to confirm the binding of siRNA onto the surface of PLGAO10H6, the
electrophoretic mobility of naked siRNA or the respective siRNA complexes
(PLGAO10H6-siRNA) was evaluated by agarose gel electrophoresis. Samples were
analyzed in 1% agarose gel (MP Biomedicals, Solon, Ohio) with or without the addition
of low molecular weight heparin sodium (Eikins-Sinn, Inc., Cherry Hill, NJ) (50 U/mL)
that can release charge-bound nucleic acids. To test the protection effects of the particles,
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free siRNA and PLGAO10H6-siRNA were incubated with 10% FBS at 37°C for overnight
prior to loading in sample reservoir.
Mice and cell line
Six to eight weeks old female certified virus free C57BL/6 mice were purchased from
Charles River Laboratories International Inc. (Wilmingto, MA, USA) and housed in the
Duquesne University Animal Care Facility. B16 (B6-derived melanoma)-F10 cell line
was obtained from American Type Culture Collection (ATCC) (Manassas, VA, USA)
and cultured in ATCC-formulated Dulbecco‟s Modified Eagle‟s Medium (DMEM)
supplemented with 10% (v/v) FBS and 1% (v/v) antibiotics.
Flow cytometric analysis of RNA uptake
Fresh splenic T cells from C57BL/6 were exposed to FAM-labeled free siRNA (3 μg)
or PLGAO10H6-siRNA in 2 ml of Opti-MEM media for 4 h at 37ºC, 5% CO2. After
incubation, cells were then washed with PBS and analyzed using a Beckman Coulter
EPICS XL bench-top flow cytometer. At least 10,000 events were sampled for each
group.
In vivo effect of Foxp3 specific siRNA carried by PLGAO10H6 particles
B16-F10 cells (passage number 5-10) were seeded subcutaneously into six to eight
weeks old female C57BL/6 mice. After 7 days, PLGAO10H6-siRNA particles were
injected intra-tumorally. 48 hours later, mice were euthanized and the spleens were
pulverized to make single cell suspension. For flow cytometric analysis, the splenic cells
were stained for CD4, CD25 and Foxp3 with fluorescent-conjugated antibodies. For RTPCR analysis, these splenic cells were selected for CD4 positive population. Total RNA
was extracted and one-step RT-PCR analysis was performed in an Eppendorf
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MasterCycler (Eppendorf, Hamburg, Germany). Murine Foxp3 primer pairs (SuperArray
Bioscience, Frederick, MD, USA) were used to generate cDNA from total RNA and
amplify the product, and mice β-actin primer pairs were used for semi quantification
purpose. The DNA products were analyzed by electrophoreses on 2% agarose gel and
visualized by ethidium bromide staining.
Tumor assay
Mice were inoculated with 0.5×106 B16-F10 cells (passage number 5-10) in 0.2 ml
PBS subcutaneously. The diameter of the tumors was measured with calipers twice at
right angles to calculate the tumor volume. Each experiment group consisted of five
mice.
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RESULTS AND DISCUSSION
PLGAO10H6-ODN particles were fabricated from PLGA polymer with the ODN precondensed with O10H6 using a double-emulsion/solvent-evaporation method (figure 71b).[139] In contrast to a similar lysine-based peptide, O10H6 is nontoxic to DCs.[144]
Ornithine is a non-natural amino acid that contains a side chain (−CH2−CH2−CH2−NH2)
that is fully protonated at physiological pH. The histidine imidazole (pKa~6.7) is partially
ionized (<5%) at pH 7.4, but is progressively protonated as pH decreases. Once inside
endosomes (pH 5–6), the histidines in O10H6 may act as a buffer and induce the vesicles
to burst by promoting influx of protons and water[137, 138] and release their content into the
cytosol.
Physicochemical characteristics of PLGAO10H6-ODN particles
The PLGAO10H6-ODN particles have an average diameter of 373.5±29nm (n=3) based
on dynamic light scattering analysis (figure 7-3 a). Additions of ODN and/or O10H6 do
not affect the particle size since blank PLGA and PLGA-ODN (referred to as no O10H6)
have similar diameters, 379±34nm (n=3) and 391±43nm (n=3), respectively. Blank
PLGA particles have an average surface charge of −14.4 ± 3.2mV (n=3), most likely due
to the PVA (surfactant) adsorbed on the surface.[145-147] As expected, addition of anionic
ODN to PLGA (PLGA-ODN) results in a more negative potential (−17.3±1.8mV, n=3)
compared to blank PLGA. Incorporation of the cationic O10H6 (in PLGAO10H6-ODN)
leads an average potential of −16.9±5.2mV (n=3 figure 7-2 b). The changes in the zeta
potentials are consistent with the respective compositions of the particles.
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Figure 7-3: Physical characteristics of PLGAO10H6-ODN particles. (a) Particle
size determined by dynamic light scattering. (b) Zetapotential: determined with
samples suspended in ddH2O. (c) Transmission electron microscopy micrograph
of PLGAO10H6-ODN (diluted 10 times) at 104 × magnification. Inset: An inverted
image of a selected particle was analyzed for circularity using the NIH ImageJ
software. Circularity was determined to be 0.7 based on the function
4π×area/perimeter2 (a perfect circle would have a value of 1.0). All data are
representative of at least three independent experiments.
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Transmission electron microscopy confirmed the spherical morphology (calculated
circularity=0.7; 1.0 indicates a perfect circle) of the particles (figure 7-3 c). Loading
efficiency of PLGAO10H6-ODN was determined to be 42.3%, which is in the same order
of magnitude in microparticles formed with PLGA and poly-L-lysine reported by Capan
et al.[124] DNA loading in PLGA-ODN was poor, at only 1.3%.
A subtractive FTIR method[148, 149] was used to confirm the presence of ODN in the
particles (figure 7-4). The spectra of PLGAO10H6 and PLGAO10H6-ODN were collected
with PLGA as the subtracted background. The addition of ODN clearly changes the
spectral profiles. The alkyl groups of the ODN can be clearly identified by the peaks at
2922 cm−1 and 2852 cm−1 assigned to C-H asymmetrical and symmetrical stretches
(figure 7-4 a). In PLGAO10H6 (without ODN), the broader bands at 3051 cm−1 and 2944
cm−1 can be attributed to the gauche conformation of the alkyl chains in peptides (figure
7-4 b). DNA structure leads to all-trans conformation of alkyl bands and a more
consistent structure across the sample compared to peptides. The sharpening of the peaks,
taken together with the changes in zeta potentials, confirms the presence of the ODN in
PLGAO10H6-ODN particles.
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Figure 7-4: Transmittance infrared spectra of PLGAO10H6-ODN. (a)
PLGAO10H6-ODN and (b) PLGAO10H6, both with PLGA as subtracted background.
x-axis, wavenumbers (cm−1); y-axis, % transmittance. Data are representative of
three independent experiments conducted.
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Flow cytometric analysis of ODN uptake in primary DCs
Bone marrow-derived murine DCs were used as the target to determine the capacity of
PLGAO10H6-ODN to deliver ODN into cells. We used flow cytometry to determine the
frequency of cells that had taken up the ODN based on FITC fluorescence. Each analysis
was conducted based on at least 104 cells. Background fluorescence was determined in
control cells that had not exposed to DNA or particles. Treatment with PLGA-ODN
(broken line) results in lower uptake compared to PLGAO10H6-ODN (dark line) (figure 75 a). Cells exposed to PLGAO10H6-ODN have a higher level of ODN than those treated
with equivalent concentration of „naked‟ ODN (thin line). Collective analysis of three
independent experiments confirmed that treatment with PLGAO10H6-ODN consistently
resulted in superior uptake compared to PLGA-ODN or „naked‟ ODN (figure 7-5 b). We
determined that 25–30% of the dendritic cells had taken up the ODN (labeled with FITC).
With PLGA-ODN particles, the same analysis yielded uptake of less than 5%. This was
expected because of the poor DNA loading in PLGA-ODN. Incorporating O10H6 into
PLGA particles clearly contributes to the delivery.
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Figure 7-5: Uptake efficiency of FITC-labeled ODN by various carriers was
determined in murine bone marrow-derived DCs. (a) Histograms from a
representative experiment of control DCs (shaded solid), ODN (thin line), PLGAODN (broken line) and PLGAO10H6-ODN (thick line). (b) Composite analysis of
data from three independent experiments showing percentage of cells taken up
the ODN. Error bars represent standard error of mean. Control DCs were
cultured under the same conditions with treatment (∗ p <0.05).
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Evidence of internalization and endosomal escape
Internalization of ODN into DCs was confirmed using laser confocal microscopy
(figure 7-6). In concordance with the flow cytometric results, we observed consistent
superior ODN accumulation in cells exposed to PLGAO10H6-ODN compared to PLGAODN (figure 7-6). Again, this was expected because of the poor loading of DNA in
PLGA-ODN. Diffused fluorescence can be seen in a cell exposed to PLGAO10H6-ODN
(figure 7-6 b, see arrow), indicating non-sequestrated ODN in the cytoplasm.
To confirm the fate of the ODN in DCs delivered by PLGAO10H6-ODN, cells were
stained with a LysoTracker (red) dye to illuminate acidic compartments. Based on the
differential localization of green and red clusters, we concluded that DNA could escape
from the lysosomes (figure 7-7). Delineation of FITC and red fluorescence in selected
clusters confirmed that ODN (FITC) could be found outside of acidic compartments
(figure 7-7 b, cluster 1). An example of internalized ODN sequestrated in an acidic
compartment is also shown (figure 7-7 b, cluster 2). Cluster 3 represents an empty
lysosome (figure 7-7 b). Inclusion of O10H6 in the current system is intended to facilitate
loading and lysosomal escape of the DNA. Although it has been reported that PLGA
itself can also facilitate endo-lysosomal escape by charge reversal in acidic
compartments,[150] the buffering capacity of the histidines in O10H6 may neutralize lactic
and glycolic acids generated in the particle interior as the polymer chains are
hydrolyzed.[151-153] Thus, O10H6 may also serve to protect the DNA from degradation
inside hydrated particles. It should be noted that Babensee and colleagues have reported
that the effect of PLGA on dendritic cell maturation is dependent upon the density (or
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surface area) of the particles.[154, 155] In our experience, this can be controlled by using
particles with high payloads (amount of DNA/density of particles), thereby minimizing
the surface area of PLGA particles the dendritic cells encountered.
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Figure 7-6: Confocal image analyses of DCs incubated with (a) PLGA-ODN
or (b) PLGAO10H6-ODN for 2 h at 37°C. The arrow indicates a region of diffused
fluorescence. Mounted slides were imaged at 100× magnification on a Leica TCS
SP-2 spectral microscope. Data are representative of three independent
experiments conducted.
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Figure 7-7: Intracellular fate of internalized ODN. (a) Image overlay of DCs
stained with LysoTracker red and incubated with PLGA O10H6-ODN. (b)
Delineation of the location of acidic compartments and ODN in the image based
on the ratio of red and FITC intensity. Data are representative of two independent
experiments conducted.

121

Delivery of anti-Foxp3 siRNA
Another application of the carrier system is to deliver RNA molecules aimed to
downregulate specific functions in T cells. In many forms of cancer, Treg cells that
express the protein Foxp3 are associated with cancer progression.[40] These cells can be
indentified by CD4 and CD25, molecules expressed on the cell surface. Foxp3 regulated
in a dose-dependent manner the development and functions of Treg cells. Suppressive
functions of peripheral Treg cells require a continuous expression of Foxp3.[156,

157]

Studies have shown that downregulation of Foxp3 can increase the ability of other
immune cells to destroy tumors, e.g. cytotoxic T cells (CTL) revert back to anti-tumor
phenotypes.[45] RNA interference (RNAi) is a mechanism in which RNA molecules bind
to and degrade specific messenger RNA (mRNA) in a sequence-dependent manner such
that expression of the encoded protein is terminated.[158] Inhibition of Foxp3 expression
can be accomplished by introducing double-stranded small-interfering RNA (siRNA)
with sequence complementary to the Foxp3 mRNA. In vitro, the activity of siRNA is
long lasting, with 50% knockdown observed up to 10 days, and is mainly limited by
dilution of the siRNA through cell division. The activity of siRNA in vivo, however, is
hindered by rapid degradation in biological fluids prior to reaching target molecules.
Efficient application of RNAi requires a carrier system to facilitate the uptake of siRNA
by cells.[159]
In this chapter, nanosized PLGA particles coated with the polycation O10H6 (with the
resultant particles designated as PLGAO10H6) was used to adsorb siRNA that bind to the
mRNA encoding Foxp3. The surface molecules CD4 and CD25 were used in quantifying
Tregs in flow cytometric analysis. The level of Foxp3 expression was estimated using
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semi-quantitative PCR. The performance of the siRNA-loaded particles was determined
in mice carrying B16 tumors in which Treg cells have been found to congregate.
Physiochemical characterization of PLGAO10H6-siRNA Particles
Zeta potential measurement showed that plain PLGA particles have an average surface
charge of -16.92±1.1mv. The surface adsorption of O10H6 and siRNA (figure 7-8 a)
caused this negative charge neutralized, resulted in an average potential of -0.30±1.0mv.
The size of the RNA-loaded particles remained below 300 nm in hydrodynamic diameter,
figure 7-8.
Heparin is a highly sulfated glycosaminoglycan, which has a high negative charge
density. In the electrophoresis, heparin was added to liberate RNA bound via ionic
interaction. In figure 7-9 a, upper panel showed that RNA were retained in loading wells
when complexed with PLGAO10H6. When heparin was added, comparable level of RNA
was released from PLGAO10H6-siRNA particles (figure 7-9 a middle panel). Serum was
used to test the ability of PLGAO10H6 to protect the RNA from enzymatic digestion and
protein destabilization. Compared to free siRNA, which were mostly degraded, RNA
complexed with PLGAO10H6 (PLGAO10H6-siRNA) remained largely intact after incubated
with 10% FBS at 37°C for overnight, figure 7-9 a lower panel. The band intensity was
quantitatively analyzed and summarized in figure 7-9 b. It shows that compared to free
siRNA, which is totally degraded in serum digestion, approximately 60% of the siRNA
were protected by PLGAO10H6 particulates and remained intact through serum incubation.
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Figure 7-8: Physical properties of plain PLGA and PLGAO10H6-siRNA
particles. (a) Mode of RNA loading and physical properties. Particle size and
zeta potential of (b) plain PLGA particles and (c) PLGA O10H6-siRNA particles. The
adsorption of O10H6 and siRNA did not change the size range of PLGA particles,
but neutralize the negative surface charge.
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Figure 7-9: Gel electrophoresis of RNA complexes. (a) Agarose (1%) gel
image. Heparin sulfate was added to liberate charge-bound RNA from the
surface of particles. In the “+serum” groups, naked siRNA or the respective RNA
complexes were incubated with 10% FBS at 37°C for overnight to test the
protection effects of PLGAO10H6 particles. (b) Relative fractions of RNA were
quantified with the free siRNA as the control.
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Uptake of RNA into primary mouse T cells
Confocal and flow cytometric analyses have been performed to test if the particles
could assist uptake of RNA into primary mouse T cells. The uptake efficiency of FAMlabeled siRNA in mouse spleen T cells was improved from 3.2±0.2% for free siRNA to
20.1±3.9% when carried by PLGAO10H6 particles. Furthermore, in CD4+ T cells, this
level was increased from 2.7±0.2% to 27.1±1.3% when PLGAO10H6 was employed. These
differences were statistically significant in three experiments conducted (p < 0.01), figure
7-10 a and b. Approximately, one in four CD4+ T cells isolated from a mouse spleen
took up FAM-labeled siRNA when loaded on PLGAO10H6, compared to one in 24 when
free siRNA were applied. Confocal imaging revealed that the RNA was internalized into
the T cells (figure 7-10 c).
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Figure 7-10: Evidence of siRNA (fluorescein labeled) in mouse T cells. (a)
Histograms from a representative experiment of flow cytometric analyses. (b)
Statistical analysis of data from three independent experiments. Error bars
represent standard error of mean. (c) Confocal images of mouse splenic T cells
exposed to PLGAO10H6-siRNA. Primary mouse spleen T cells were incubated with
PLGAO10H6-siRNA particles for 4 hours at 37°C. Images were captured by a Leica
confocal microscope at 63× magnification.
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In vivo function of PLGAO10H6-Foxp3siRNA particles in mouse B16 melanoma tumor
model
B16 tumor-bearing C57BL/6 mice were treated with PLGAO10H6-Foxp3siRNA
particles. Spleen T cells were taken from these mice and fluorescently stained for CD4,
CD25 and Foxp3. Flow cytometric analysis showed that Treg cells, measured based on
cells expressing a high level of CD25, decreased from 24% to 14% in splenic CD4+ T
cells. While measured based on intracellular expression of Foxp3, Treg cells decreased
from 14% to 11% in CD4+CD25+ cells, figure 7-11 c. RT-PCR analysis (figure 7-11 d)
showed that Foxp3 transcripts were downregulated about 50% in CD4+ spleen T cells
isolated from these mice. Negative RNA that does not target any endogenous transcript
was used as a control for nonspecific effects on gene expression caused by introducing
any siRNA.
In figure 7-12, retarded tumor growth was observed in mice subjected to PLGAO10H6
complexed with Foxp3 siRNA. Although the tumor would grow out eventually, the
growth was delayed at the primary phase. Particles were injected when lesions were
visible (5-7 days after B16 inoculation). It is envisioned that the regimen would be
effective as an adjuvant when combined with cancer vaccines or chemotherapy. Mice
administered with the particles or particles complexed with the siRNA showed no overt
signs of acute toxicities.
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Figure 7-11: In vivo effects of PLGAO10H6-Foxp3 siRNA particles. (a)
Schematic of in vivo function study. (b) Surface and intracellular molecules
expressed by Treg cells. (c) Flow cytometric analysis showed that CD4+CD25 high
T cells and CD4+ CD25+Foxp3+ T cells were down regulated in vivo. (d) Foxp3
mRNA expression in spleen CD4+ T cells taken from PLGA O10H6- siRNA treated
mice. Bands identified were consistent with predicted PCR products of Foxp3
and β-actin at 221 and 302 bp, respectively. Negative RNA, that does not target
any endogenous transcript, was used as a control for nonspecific effects on gene
expression caused by introducing any siRNA.
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Figure 7-12: B16 melanoma tumor growth in mice treated with Foxp3siRNAloaded or empty particles. Each experimental group consisted of five mice.
Error bars represent standard error of mean. The difference between the two
groups is not statistically significant (p=0.137). In the group treated with
PLGAO10H6-Foxp3siRNA, 5μg siRNA were used for each mouse.
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SUMARRY AND CONCLUSIONS
The present study shows that efficient delivery of ODN into primary DCs can be
achieved with PLGAO10H6-ODN. The change in the zeta potentials and the infrared
reflectance analysis indicate the presence of both O10H6 and ODN in the particles
(figure 7-3 and 7-4). The colloidal nature of the particles suggests the system is a stable
formulation. The combination of PLGA and O10H6 in particle formation is superior to
PLGA or with O10H6 alone in the delivery of ODN (figure 7-5 and 7-6). Importantly,
internalized ODN can escape from lysosomal degradation, suggesting that effective
concentration can be attained in the cytosol (figure 7-7). In conclusion, the physical
characteristics and cellular uptake of DNA loaded particulates fabricated with PLGA and
O10H6 were reported. This unique combination should be further investigated for
developing carriers of DC modulators.
In the delivery of Foxp3 specific siRNA, the change in surface zeta potential and
electrophoretic pattern of the complexes indicated adsorption of the RNA onto the
PLGAO10H6 particles (figure 7-8). The size of the RNA-loaded particles remained below
300 nm in hydrodynamic diameter. Additionally, PLGAO10H6 particles protected siRNA
from serum digestion (figure 7-9). Confocal and flow cytometric analyses showed the
particles assisted uptake of RNA into primary mouse T cells (figure 7-10). Mice
administered with Foxp3-siRNA complexed with the particles had lower frequency of
Treg cells (figure 7-11 c) and decreased expression of Foxp3 transcripts (figure 7-11 d).
Early results revealed that intra-tumoral injection of the Foxp3-siRNA particles caused a
delay in B16 tumor growth in mice (figure 7-12). In conclusion, the polymeric particle
PLGAO10H6 facilitated the delivery of siRNA in primary mouse T cells. When complexed
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with PLGAO10H6, Foxp3 specific siRNA is effective in down-regulation the level of
Foxp3 in vivo.
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CHAPTER 8
SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS FOR: A PEPTIDEBASED PLATFORM FOR DISPLAYING ANTIBODIES TO ENGAGE T CELLS

In this work, I investigated the EAK-EAKH6 composite as a mAb-displaying platform
and a potential nucleic acids delivery system. In this concluding narrative, I summarize
the main findings from the aforementioned studies and share some of my thoughts in the
next step in advancing the concept towards application.
A series of experimental studies were performed to test the concept that assembly of
amphiphilic peptides could be exploited biomedically through functionalization. Chapter
4 contains data showing integration of EAKH6 into the EAK structures. When the
mixture of EAK and EAKH6 was exposed to physiological concentration of salts
solution, e.g. PBS, an insoluble, gel-like structure formed. Whereas EAKH6 itself
remained in solution, about 50% of the EAKH6 was removed from the solution when
mixed with EAK. The composite was found to be stable at 37°C for at least 7 days.
Upon establishing the EAK-EAKH6 composite with H6 domains for binding, Chapter 5
sets out to determine whether this design can be used to load mAb to the peptide
assembly. rpAG proved to be a reliable adapter to link anti-H6 antibody and capture
mAb. The data show unequivocally immobilization of mAb onto the EAK-EAKH6.
Importantly, the construct could be formed in vivo; aggregates displaying a fluorescentlabeled mAb could be observed when a mixture of EAK, EAKH6, rpAG, anti-H6 and
IgG (PE) dissolved in water was injected subcutaneously next to a tumor in a mouse. The
anti-CD4 construct was shown to capture CD4 positive cells in a mixture of mouse
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lymphocytes. Collectively, the results indicate that the insoluble peptide structure can
cluster mAb in which the antigen-binding function remains intact. This work thus raises
the prospect of using EAK-EAKH6 as an antibody delivery platform to modulate
immune cells inside or near pathogenic locales. The “reversed drug targeting” concept, to
be elaborated below, requires a mechanism to build a reservoir of drug molecules for colocalization with captured cells. To this end, polymeric particles were explored as drug
loading mechanisms (Chapter 7).
Monoclonal antibodies have emerged over the past decade into a mainstay of
therapeutic options for a wide range of diseases, including autoimmunity, inflammation,
cancer and organ transplantation. However, the clinical efficacy of therapeutic antibodies
is limited. It is caused by short serum half-life, systemic side effects, or lack of effector
functions which are Fc-mediated antibody properties that involved in target cell
destruction: antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent
cellular phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC). As an
alternative, additional functions can be endowed on antibodies by conjugation to other
drugs. In cancer therapy, antibodies or the antigen binding fragments (Fab) can be
conjugated with radioactive isotopes, chemotherapeutics, toxins or the surface of drugloaded particles/liposomes to create highly targeted agents.[2] In diagnostic techniques,
antibodies are conjugated to light-active molecules, e.g. quantum dots[160], for live
imaging. Additionally, drugs conjugated to insulin receptor antibodies can achieve
significant brain delivery through receptor-mediated transport.[161] However, using
immobilized mAb to capture cells has not been examined extensively. This strategy could
potentially provide a novel application of mAb, by which the limitations of rapid
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degradation and poor tissue penetration can be avoided. Although this approach is
restricted to cell surface molecule specific antibodies; and the target cells have to be
leukocytes that are capable of migrating via diffusion, it suggests a new idea to design
and use mAb.
Self-assembling peptides have been explored extensively for drug delivery,
including small molecules and proteins. Most of them are loaded by physically mixing
with the peptides; therefore the release kinetics are significantly varied due to various
interactions (could be electrostatic interaction or hydrophobic interaction) between the
drugs and the peptides. To achieve controlled delivery, self-assembling peptides can be
biotinylated, which allows binding with high affinity to any molecule (such as a protein)
that can be biotinylated using strepavidin.[73] However, typical conjugation methods
require the use of organic solvents, resulting in at least partial denaturation detrimental
effects on the biological activity of themacromolecules. Self-assembling peptides can
also deliver signals by fusion proteins designed with incorporating proteins at the N- or
C-terminus of the sequence of self-assembling peptides by a linker sequence.[74] This
method is limited due to lack of versatility, since each peptide-drug conjugate would have
to be custom synthesized. Our work demonstrated that H6 domain could be introduced
into the EAK assembly as a way to introduce binding sites. Thus the points of
functionalization are an integral part of the structure. This strategy confers a degree of
flexibility, for the specificity of the construct can be readily changed by simply using a
different mAb. The most promising aspects are the injectability of all components as a
solution and the reconstitution of the structure in vivo.
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Abnormally skewed lymphocytes populations have been reported in cancer patients.
Although the primary solid tumor can be removed by surgery or killed by chemotherapy,
the tumor-favored trend still exists in the patient‟s immune system, which allows the
reoccurrence of the tumor, or even worse, metastasis. This work suggested an immunefocused strategy as a potential post-surgery treatment to reduce the incidence of
reoccurrence, rather than directly target the tumor cells.
The demonstrated ability to capture cells is an important validation. Conventionally
“targeted drug delivery” refers to chemical (e.g. ligand) or physical (e.g. magnetic)guided localization of agents to diseased tissues (e.g. tumor). However, T cells are
usually widely distributed in the pathogenic sites and difficult to be targeted. It has been
reported that less than 5% of the entire tumor cellularity are infiltrated lymphocytes.[41]
Therefore, the traditional drug delivery may not work efficiently. Taking the advantage
that a specific subset T cells could be congregated in the peptide structure, we herein
suggest a new concept of reversed drug targeting. In this reversed approach, the drugs are
immobilized while the target cells are brought to the drugs. Even the antibody is not
potent enough to cause the target cells destructed; other therapeutics can be pre-loaded to
the peptide assembly. In the work of Chapter 7, we employed PLGA particles as delivery
vectors for nucleic acids to DCs and T cells. These PLGA particles could be decorated
with nickel by incorporating Ni-NTA-DOGS in the primary polymer solution. These
PLGANi particles have been tested in a study described in chapter 9. It would be of great
interest to load PLGANi particles as drug carriers onto the EAK-EAKH6 composite
through coordination with the H6 domain. With each component characterized, it is thus
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possible to develop a system to test the concept of reversed drug targeting by bringing
specific cells (via mAb) to a reservoir of drug molecules (particles).
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CHAPTER 9
The experiments described below were part of a separate project concerning genetic
modification of allogeneic transplant tissues. The study lies outside the scope of the main
thesis described in the chapters above but nevertheless represents an element in of my
graduate work.

MODULATION OF ALLOGRAFT IMMUNOGENICITY WITH IL-10 GENE
PARTICLES

INTRODUCTION
More than 20,000 patients undergo solid organ transplantation every year in the U.S
(source: Organ Procurement and Transplantation Network: http://optn.transplant.hrsa.
gov/). Organ transplantation improves the quality of life for patients suffering from
otherwise incurable diseases, including those of cardiovascular nature and malignancies.
Inhibitors of T cell receptor signaling (e.g. tacrolimus) represent the mainstay in
managing transplant rejection.[162-164] These agents exert their therapeutic effects by
dampening the cytolytic actions of all T cells. Patients exposed to these drugs chronically
have increased risks of developing opportunistic infections and malignancies.[164]
Consequently, transplant recipients rarely live to normal life expectancy. In most cases,
the initial encounter between the allograft and recipient‟s immune system dictates the
outcome. Attenuating acute rejection improves the long-term viability and function of the
transplant. The time between organ harvest and implantation provides an opportunity to
modulate the immunogenicity of the allograft, prior to encountering recipient‟s T cells in
vivo. We envision that during the transit period (up to 24 hours), between organ harvest
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and implantation, gene treatment can be applied as an ex vivo intervention to generate
selective immunosuppression. The health impact of the proposed research lies in
developing new strategies enabling tapered use of non-specific immunosuppressive drugs
in transplant recipients by reducing the incidence and severity of acute rejection.
Interleukin-10 (IL-10) is an anti-inflammatory cytokine that has been used to induce
allograft tolerance in animal models. IL-10 regulates the functions of neutraphils, mast
cells, T cells, macrophages, and other tissues,[165] but the protective effect of the cytokine
on allografts is mediated primarily through DCs.[166-168] DCs cultured with IL-10 have
been shown to impair the ability of T cells to produce INF-γ,[169] a cytokine that drives
the killing function of cytotoxic T cells (CTLs). In vivo, protection of allgrafts by IL-10
producing DCs often develops concomitantly with the expansion of Treg cells.[170-172]
Treg cells restrain the proliferation and activation of CTLs.[173] Suppressive function of
Treg cells are mediated by TGF-β[174] and CTLA-4.[175] In mice, Treg cells inhibit
migration of CTLs from draining lymph nodes to allografts.[176] Foxp3+ cells have been
found in accepted allografts[177] and in lymph nodes of animals with long-lived
transplants.[178] Because of Treg cells‟ potential to curtail allograft rejection, the success
of the ex vivo IL-10 gene treatment will be measured based on Foxp3 expression in
recipient T cells.[118, 179-182] Because of DCs‟ ability to dictate the activities of naive T
cells, protection of allografts can be achieved by inducing DCs to produce IL-10 to
inhibit T cells activation in transplant recipients.[117, 183] IL-10-producing DCs have been
tested as cellular therapy in transplant models.[183, 184] From a logistical standpoint, ex
vivo treatment of allografts is superior to cellular therapy using the patient‟s own DCs.
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Genetic modification of DCs to express anti-inflammatory cytokines is proposed as a
strategy to mitigate transplant rejection.[185-187] A current challenge is to develop effective
methods to transfer immunosuppressive cytokine genes into DCs without using viruses.
Compared to chemical methods, viral vectors generally confer superior transfection
efficiency, but humoral and cell-mediated immune responses triggered by viral
components can interfere with the inhibitory actions of IL-10.[188] Non-viral systems are
less immunogenic; but it was thought that DCs do not divide in situ and thus refractory to
non-viral methods of transfection without the aid of pro-inflammatory stimuli.[189,
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Data emerging in the past three years, however, have challenged this assumption. Using
live-cell imaging techniques, it has been demonstrated that up to 5% of mouse DCs
undergo division in vivo.[191, 192] Similarly, 2-3% of human DCs are proliferating in situ at
any given time.[191] The fact that DCs undergo proliferation when residing in tissue makes
it possible for in situ gene transfer in DCs using non-viral means.
Studies performed previously in our lab show that PLGA modified with the cationic
peptide O10H6 (PLGAO10H6) were effective in delivering a mouse IL-10 encoding
plasmid (pIL-10) to skew bone marrow-derived DCs to downregulate T cell responses. T
cells stimulated by the IL-10 gene-modified DCs exhibited characteristics of Treg cells,
as evident by upregulation of Foxp3 transcription factor concomitant with an increase in
TGF-β production. It can therefore be concluded that PLGAO10H6 complexed with pIL-10
delivered an overriding suppressive signal to T cells. Physical characterization of
PLGAO10H6-pIL-10 revealed a stable colloidal dispersion. DNA molecules carried by
PLGAO10H6 were protected from serum digestion.[193] To obtain a stronger binding
mechanism with O10H6, nickel ions were incorporated into the matrix of PLGA particles
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using the metal chelating lipid DOGS-NTA-Ni. These particles were referred to as
PLGANi particles. Binding of O10H6 raised the surface potential of PLGANi from -17mv
to +13mv. This change was partially reserved by the presence of free imidazole,
suggesting the binding was mediated by nickel-histidine coordination. When compared to
PLGA particles without nickel (40.8%), ODN bound to O10H6 coated PLGANi particles
(PLGANi-O10H16) exhibited enhanced capacity (71.9%) to accumulate in DCs cultured in
vitro. DCs exhibited cellular stress after exposure to PLGANi-O10H16-DNA, but this effect
can be prevented by serum and was reversed overnight.[194]
In this chapter, PLGANi-O10H16 particles were used to carry pIL-10 to reduce the
immunogenicity of skin allografts. The presence of DCs in skin explants was confirmed
by MHC-II antibody staining. Successful transfection was evidenced by the increased IL10 release. Reduced immunogenicity was shown by lower INF-γ production in co-culture
of skin grafts with allogeneic T cells.
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MATERIALS AND METHODS
Plasmid and PLGANi-O10H6-pIL-10 complexation
Plasmid encoding murine IL-10 (figure 9-1, pUMVC3-mIL10; 4563 bp) was obtained
from Aldevron (Fargo, ND, USA), aliquot in distilled water and stored in -80°C until use.
The IL-10 gene in this vector is driven by the cytomegalovirus promoter/enhancer with
trimmed intron A and a rabbit β-globin polyadenylation signal.
PLGANi particles were prepared using a double emulsion (w/o/w) solvent evaporation
method, which was described in chapter 7, with metal chelating lipid DOGS-NTA-Ni
incorporated in the polymer MeCl2 solution. Briefly, 90mg PLGA and 0.6 mg DOGSNTA-Ni were dissolved in 3 ml MeCl2. To this organic phase 200μl ddH2O was added
and sonicated (24W) for 2 min. The resultant primary emulsion was added drop wise
with energy input again (24W, 4min) to 20 ml of ddH2O and the resulting mixture was
allowed to evaporate for 4 h to remove MeCl2. Particles were washed twice in ddH2O and
recovered by centrifugation. Plasmid loading was accomplished by first coating the
particles (30μl from 4.5mg/ml stock) with O10H6 (60μg) followed by addition of
plasmids (pIL-10, 5μg) in 300μl ddH2O.
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Figure 9-1: Mammalian expression vector for mouse IL-10. (obtained from
Aldevron, Fargo, ND.)
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Generation of skin explants and IL-10 gene transfer
Donor skin was harvested from euthanized Balb/c mouse by cutting eat off at base.
Ventral and dorsal sides of tissue at base of ear were gently pulled apart. The dorsal
tissue was collected with internal surface down in serum free OptiMEM media
(Invitrogen, OR, USA). To visualize the DCs in dorsal sheets, PE (phycoerythrin)conjugated I-Ad antibody was added to stain the MHC-II molecules expressed on the
surface of DCs. PLGANi-O10H6-pIL-10 complex was added to the cultures and incubated
for 2 hours at 37°C in 5% CO2. Media were then removed and replaced with fresh
complete RPMI 1640 (Mediatech, VA, USA) containing 10% FBS and GM-CSF/ IL-4
(R&D Systems, Minneapolis, MN).
Co-culture of skin grafts with allogeneic T cells and ELISA
As the schematic shown in figure 9-2, transfected skin grafts were cultured with
splenocytes of mismatched mice C57BL/6 (H-2b). The splenocytes were depleted of red
blood cells and monocytes prior to co-culture. 1×106 T cells were seeded with each skin
graft in 1 ml complete AIM V medium (Invitrogen, OR, USA) and incubated for 24
hours in a humidified 37°C, 5% CO2 incubator. Concentrations of IL-10 and INF-γ were
determined in the culture supernatants using the ELISA DuoSet kit (R&D Systems, MN,
USA) according to the manufacturer‟s protocol.
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Figure 9-2: Schematic of co-culture of skin grafts and allogeneic T cells.

145

RESULTS AND DISCUSSION
Under confocal microscope, the presence of DCs in dorsal sheets isolated from mouse
ear skins was demonstrated using red fluorescent-conjugated antibodies specific to the
MHC-II molecule I-Ad expressed only on DCs and DC-like cells (figure 9-3 a).
Successful transfection was evidenced in the increased IL-10 release by the explants. A
2-fold increase (p=0.0002) in IL-10 expression was found in skin cultures transfected
with PLGANi-O10H6-pIL-10 compared to control plasmid (figure 9-3 b). Reduced
immunogenicity is shown by lower INF-γ production by allogeneic T cells mixed with
skin exposed to PLGANi-O10H6-pIL-10. More than 5-fold higher INF-γ (p=0.001) was
found in T cells stimulated by skin explants transfected with PLGANi-O10H6 complexed
with control plasmid compared to those transfected with PLGANi-O10H6-pIL-10 (figure 93 c). In the same skin-T cell cultures, higher level (2-fold difference, p=0.005) of IL-10
was produced when the IL-10 gene particles were applied compared to when a control
plasmid was used (figure 9-3 d). These results show a definitive inhibitory state of donor
DCs, and support that the IL-10 gene particles can reduce immunogenicity of the
allograft in vivo.
The principle targets of the immune response to allogeneic grafts are the MHC
molecules, which are highly polymorphic within species. Since laboratory mice are
inbred, each strain is homozygous and has a unique halotype. For example, the MHC
haplotype of Balb/c is H-2d, and C57BL/6 is H-2b.[4] The recognition of allograft MHC
antigen is the primary event that ultimately leads to graft rejection. T cells involved in
graft rejection can be sensitized against alloantigens via one of two distinct pathways:
direct and indirect. In the direct pathway, organ grafts carry with them APCs of donor
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Figure 9-3: Effects of PLGANi-O10H6-pIL-10 particles on the immunogenicity
of intact skin explants. Excised mouse ears (BALB/c) were rinsed with 70%
ethanol and split into dorsal and ventral halves. Dorsal halves were cultured in
OptiMem media and subsequently exposed to PLGA Ni-O10H6-pIL-10 particles or a
control plasmid. After transfection skin, explants were incubated in culture
medium for 48 h prior to mixing with T cells for an additional 24 h. The skin
explants contain high density of DCs (384/mm2; enumerated using a Zeiss
AxioObserver Z1 inverted microscope), as indicated by a phycoerythrin (red)
anti-BALB/c MHC-II antibody with parenchmyal cells countered stained with
fluorescein (a). Supernatants from skin (b) and skin-T cell cultures (d) were
analyzed for IL-10 concentration and in the latter case INF-γ release as well (c).
Student’s t-test was used to determine statistical significance of the ELISA
results. Detection limits of IL-10 and INF-γ ELISA were 4 pg/ml and 15 pg/ml,
respectively.
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origin. These APCs leave the graft and migrate via the lymph to regional lymph nodes,
activate those host T cells that bear the corresponding T-cell receptor. The activated
alloreactive effector T cells are then carried back to the graft, which they attack directly.
The ligand of the alloreactive T cell is the allogeneic MHC molecule itself. A second
mechanism leading to graft rejection is the uptake of allogeneic proteins by the
recipient‟s own APCs and their presentation to T cells by self-MHC molecules. This way
is known as indirect allorecognition. Direct allorecognition is thought to be largely
responsible for acute rejection, especially when MHC mismatches mean that the
frequency of directly alloreactive recipient T cell is high.[195,
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Therefore, genetic

modification of donor DCs to express immunomodulatory molecules represents an
effective strategy to prolong graft survival.
When the naive T cells from C57BL/6 (H-2b) are exposed to mismatched Balb/c (H-2d)
DCs in the skin grafts, they are activated to undergo proliferation, differentiation and
production of effector molecules. Among them is a main cytokine INF-γ released by CD8
effector T cells and TH1 cells. Hence the expression level of INF-γ is a good quantitative
index of the extent of host T cells can be activated. The results showed in figure 9-3
indicate a significantly decreased mixed reaction between host T cells and donor DCs by
transfected with pIL-10. A possible protection regimen for skin grafts by PLGANi-O10H6pIL-10 is suggested.
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